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Acute myeloid leukemia (AML) is a malignant tumor characterized by the uncontrolled 
proliferation of immature hematopoietic cells (blasts) that colonize the bone marrow 
leading to a malfunctional hematopoiesis. Despite the efforts to search for new therapies 
and the identification of new targets, leukemias are still largely incurable. The main reason 
for treatment failure is the high frequency of relapses after remission induced by the first 
chemotherapy treatment. Recent studies suggest that the high rate of relapse is due to the 
presence of cells with limitless regenerative capacity, Leukemia Initiating Cells (LIC), that 
are very resistant to chemotherapy. Moreover, since the leukemic blasts are highly 
heterogeneous both from a biological and genetic point of view, AML evolves 
continuously under both environmental and external stimuli (eg, chemotherapy). 
In order to study the clonal evolution of AML and to find new therapeutic targets that 
allow to eradicate leukemic blasts, this study has set the following objectives: i) monitor 
LICs growth in vivo through the transplantation of traceable leukemic cells; ii) investigate 
the clonal evolution of the disease; iii) identify genes critical to tumor growth in vivo that 
can become new therapeutic targets.  
To address these issues, we have used two lentiviral libraries (Cellecta Inc.): i) a clonal 
tracking library composed by 30 million different barcodes; ii) an shRNA library 
composed by ~1000 different shRNA able to silence ~100 genes. The libraries were used 
to infect xenotransplants of patient-derived leukemias and murine leukemias obtained from 
mouse models. The infected blasts were transplanted in recipient mice and, following 
leukemia development in vivo, the DNA extracted from infected blasts has been used, 
through massive sequencing techniques, to investigate leukemia growth and evolution 
(clonal tracking library) and genes required for AML growth (shRNA screening). 
Our clonal tracking analysis highlighted a strong clonal selection troughout leukemia 
evolution with the disappearance even of clones that were present at very high frequency 
within the tumor population. Nonetheless, the clonal composition of all tumors appeared to 
be very similar in terms of number of clones, of their frequency distributions and even of 
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their identity. Taken all together, our data strongly support a model in which each LIC is 
endowed with an intrinsic and highly variable replicative potential, with the vast majority 
of LICs that are not immortal and do not possess an indefinite self-renewal ability As a 
consequence, each leukemia possesses a definite and small number of LICs able to 
propagate the disease long-term. These LICs tend to overgrow all other clones and to 
constitute a very large proportion of the tumor. 
Concerning the shRNA screening, we believe we set up an innovative in vivo approach that 
allowed us to identify putative therapeutic targets involved in the growth of primary 
tumors in their natural environment and that is mainly selective for targeting the CSC 
population. Most of the identified potential targets have been already reported to play a 
fundamental role in different types of cancer, including leukemia. Because we were able to 
perform our screening on several AMLs and identified both tumor-specific and tumor-wide 
putative targets, our study might offer solutions of therapeutic intervention in a wide group 
of AML patients, hopefully increasing their survival and decreasing therapy related side 
effects. 
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1.1 Origin and development of blood cells: hematopoiesis 
The blood contains several different cell types. Each of these cell types is quite distinct in 
appearance, and each has a specific biological function. Despite this extreme structural and 
functional heterogeneity, strong evidence exists that all the blood cells derive from a single 
cell type: the hematopoietic stem cell (HSC). The processes involved in production of all 
the various cells of the blood from the HSCs are called hematopoiesis. Hematopoiesis, that 
begins early during embryogenesis and undergoes many changes during fetal and neonatal 
development, includes HSC self-renewal, HSC commitment to specific lineages, and 
maturation of lineage-committed progenitors into functional blood cells. The mature blood 
cells have finite life spans, which vary depending on the cell type. For this reason, during 
the lifetime of an individual, mature cells are constantly replaced as the oldest cells are 
removed and the new one formed. Because mature blood cells are predominantly short 
lived, hematopoietic stem cells (HCSs) are required to replenish the multilineage 
progenitors and the precursors committed to individual hematopoietic lineages1.  
 The existence of HSCs and their capacity for extensive self-renewal have been 
demonstrated by animal reconstitution experiments with murine hematopoietic cells that 
were individually genetically marked. In these pioneering experiments, the authors 
infected blood cells in vitro with a recombinant retrovirus able to integrate randomly into 
the genomic DNA of the host cell, providing a specific marker to track the progeny of 
those cells in vivo. Each unique integration allows to distinguish and to identify the 
progeny originated from each infected cell based on the size of the bands derived from the 
genomic DNA after digestion with a restriction enzyme that does not cut the provirus. In 
the recipient mice of these marked cells, it was observed that, even several months after 
transplantation, all types of cells in the blood and lymphoid organs derive from an 
individually marked cell, proving that the cell of origin was multipotent. Moreover, these 
clones of marked cells continued to contribute to all the hematopoietic lineages for an 
extended period of more than 8 weeks and also following serial transplantation in 
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secondary and tertiary recipients. These experiments demonstrated that these cells are able 
to reproduce themselves (self-renew) over a long period of time and that long-term 
reconstitution of both the myeloid and lymphoid compartments can be achieved by 
transplantation of a single murine HSC, indicating that a single HSC is the smallest 
repopulating unit in mouse2 .  
However, in the HSC compartment, the stem cells are heterogeneous with respect to their 
ability to self-renew. The actual hierarchical model of hematopoiesis suggests that the HSC 
pool consists of at least 2 functionally distinct subpopulations: long-term and short-term 
repopulating HSCs (LT-HSCs and ST-HSCs, respectively). The LT-HSCs have extensive 
(life-long) self-renewing potential and on commitment give rise to ST-HSCs with more 
restricted self-renewing capacity. The LT-HSCs are the only cells able, following 
transplantation procedures in lethally myeloablated recipients, to give to the totality of 
blood cells for more than 8 weeks 2 .   
Transplantation assays in limiting dilutions, up to single-cell, in combination with the 
isolation of cell subpopulations based on the expression of unique cell surface markers 
profiles have allowed the isolation of at least another class of multipotent cells with short 
term (ST-HSCs) reconstitutive potential. Indeed, it has been shown that ST-HSCs can 
differentiate into all types of blood cells, however, they have a more limited self-renewal 
capacity compared to LT-HSCs and are able to give rise to the blood lineages for only 8–
12 weeks. Recently, Dick and colleagues demonstrated that transplantation of a single 
human CD34+ CD38− CD45RA− Thy1+ Rholo CD49f+ cell into immunocompromised 
mice provides multilineage reconstitution, indicating that also in humans the HSC is the 
smallest repopulating unit3.  
The process of hematopoiesis can be described as hierarchical, with at the top the LT-
HSCs, that self-renew for all the lifetime of an individual, and originate ST-HSCs.  These 
cells progress to multipotent progenitor cells (MPP), an intermediate progenitor stage that 
commits to one of the two oligo-lineage restricted cells: the common lymphoid progenitors 
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(CLPs) and the common myeloid progenitors (CMPs).  CLPs are restricted to give rise to 
T-lymphocytes, B-lymphocytes and Natural Killer (NK) cells whereas CMPs are 
progenitors for the myeloerythroid lineage. Therefore, the CMPs give rise to 
megakaryocyte-erythrocytes progenitors (MEPs) and granulocytes-macrophage 
progenitors (GMPs). Finally, these progenitors provide the entire lineage-committed 
effector cells of the blood system. In physiological situation, each stage of differentiation 
of the multipotent cells involves functionally irreversible maturation steps and no 
dedifferentiation or transdifferentiation is permitted between haemato-lymphoid 
progenitors4 (Figure 1). 
 
 
Figure	   1.	   The	   hierarchy	   of	   the	   hematopoietic	   system. LT-­‐‑HSC,	   long-­‐‑term	  repopulating	   HSC;	   ST-­‐‑HSC,	   short-­‐‑term	   repopulating	   HSC;	   MPP,	   multipotent	  progenitor;	   CMP,	   common	  myeloid	   progenitor;	   CLP,	   common	   lymphoid	   progenitor;	  MEP,	   megakaryocyte/erythroid	   progenitor;	   GMP,	   granulocyte−macrophage	  progenitor.	   The	   encircled	   pluripotent	   populations,	   LT-­‐‑HSC,	   ST-­‐‑HSC	   and	   MPP,	   are	  characterized	  by	  a	  surface	  markers	  profile	  defined	  as	  Lin-­‐‑,	  Sca-­‐‑1+,	  c-­‐‑kit+	  (LSK)5. 
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1.2 Hematopoietic stem cells and cancer stem cells 
As already described, HSCs are the only cells able to maintain haematopoiesis by their 
multipotency and self-renewal potential6. The HSCs are present in the bone marrow in 
about 0.01–0.2% of the total mononuclear cells. They are largely quiescent, and this allows 
them to preserve their genomic integrity. Indeed, frequent cell cycle and consequential 
DNA replications can introduce DNA mutations inducing oncogenic transformation7. This 
quiescent state also protects the HSCs from exhaustion and their activation occurs under 
stressful situations, such as blood loss or infections8,9. 
Self-renewal is the key biological property of stem cells. It allows each stem cell, after cell 
cycle and cytodieresis, to produce one or two daughter stem cells through asymmetric or 
symmetric division, respectively. In any case the daughter stem cells retain the self-
renewal capacity, ensuring that the stem cell population is maintained or expanded for 
long-term clonal growth. The HSCs reside in specific niches in the bone marrow and their 
homeostasis is regulated by a complex interplay of factors, such as interleukins and 
chemokines that govern HSCs fate decisions6.  
As for other tumours, also for AMLs, it has been possible to show by xenotransplantation 
models the existence of cancer stem cells responsible for driving and sustaining the 
disease: these cells have been called leukaemia-initiating cells (LICs)10. Such as HSCs, 
LICs also stay at the apex of a leukemic differentiation hierarchy and give to all leukemic 
cells. LICs and HSCs share many functional and molecular characteristics. Indeed, LICs 
may be considered as the malicious and functional counterpart of HSCs in the 
hematopoietic tumours. Due to their self-renewal ability, LICs maintain the disease 
producing the so called blasts, which are highly proliferative, have a block in terminal 
differentiation and defect in apoptotic mechanisms11,12. Moreover, proprieties like 
quiescence, increased efflux pump activity and localization in distinct bone marrow niches, 
similar to the one that characterize the normal HSCs, make the LICs rather resistant to 
various standard therapies13,14. However, these common characteristics should not imply 
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that the LICs necessarily originate from HSCs that acquire the first transforming 
mutations.  In fact, the use of several murine leukemia models has yielded conflicting 
results regarding the identity of the cells of origin of leukemias. While some fusion 
oncogenes, such as MLL-GAS7, seem to be able to initiate leukemias only when expressed 
in multipotent progenitors (MPP)15, others, such as PML-RAR, have more mature myeloid 
committed progenitors as targets for leukemic transformation (Figure 2).  
 
 
Figure 2. The leukemia-initiating stem cell model. Functional studies on acute myeloid 
leukemia have led to the identification and characterization of the leukemia initiating cells 
(LICs), which share similar biological features with the normal hematopoietic stem cells 
(HSCs). LICs can derive either from HSCs, but also from other type of cells such as 
multipotent progenitors (MPPs), committed progenitor cells or even more differentiated 
cells that accumulate mutations that restore the stem cell features  required to generate and 
regenerate tumors16.  
 
Moreover, heterogeneity in terms of self renewal potential has been observed even within 
the same tumour. Indeed Hope et al. retrovirally transduced primary human AML cells 
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with a GFP construct to track the leukemic cells in vivo, through its integration site, after 
transplantation into NOD-Scid mice10. This clonal evolution study revealed that the clonal 
population of cells initially populating host mice was disappearing after approximately 12 
weeks and being replaced by a population not detected earlier. This findings show that 
LICs are not functionally homogeneous but, like the normal HSCs, comprise distinct 
hierarchical classes. Analysis of the clonal integration sites in secondary and tertiary 
recipients revealed that often clones detectable in the primary mouse were also present in 
the secondary mouse, indicating self-renewal of this clonal population in the primary 
mouse. Interestingly, as for their normal counterpart, some clones were contributing to 
leukemia engraftment persistently for >12 weeks in the primary recipients but consistently 
failed to engraft for more than 12 weeks in secondary and tertiary recipients. This can be 
considered as evidence that short-term LICs arise from long-term LICs, which are believed 
to be quiescent and likely persistent below the detection limit in the primary recipients10. 
 
1.3 Leukemia 
Leukemia is defined as a cancer that affects the bone marrow and results in abnormal 
proliferation of white blood cells, also called leukocytes. Different types of leukemia exist 
and they can be classified according to the type of blood cell that is affected and to how 
quickly the disease develops and progresses.  
According to the time of evolution of the disease, leukemias can be classified in acute and 
chronic. In acute leukemias, the blasts remain in a immature state with the impossibility to 
carry out their normal functions. In this type of leukemia, the blasts increase rapidly in 
number with a consequent rapid worsening of the disease. In chronic leukemia, the blasts 
are more mature and maintain the ability to carry out some of their normal functions. In 
this case, the increase in blasts number is less rapid and the development of the disease 
slower compared to the acute diseases17. 
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Depending on which lineage is affected, leukemia can be subdivided in two main 
categories: myeloid and lymphoid. In the myeloid leukemia cells of the myeloid lineage 
such as granulocytes, monocytes, erythrocytes or megakaryocytes are involved. In the 
lymphoid leukemia cells of lymphoid lineage such as B-cells, T-cells or natural killer 
(NK)-cells are involved17.  
Based on the two parameters described above, it is possible to classify the leukemias in 
four main categories: acute myeloid leukemia (AML); chronic myeloid leukemia (CML); 
acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL)18. The 
studies presented in my thesis are performed exclusively on samples of AML, therefore I 
will focus my attention and describe in more detail only this type of leukemia. 
1.4 AML 
Acute myeloid leukemia (AML) is the most frequent haematological malignancy in adults 
and accounts for ~75% of all acute leukemias, with an estimated worldwide annual 
incidence of 3-4 cases per 100,000 people19. The two main systems used to classify AML 
into subtypes are the French-American-British (FAB) classification and the more recent 
World Health Organization (WHO) classification. In particular, the FAB classification was 
elaborated in the 1970s and is based mainly on morphological appearance of the blasts and 
their cytochemistry the FAB classifies the AML diseases into categories from M0 to M7, 
according to the type of cell from which the leukemia develops and the degree of 
differentiation of the leukemic cells20 (Table 1). 
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Table 1. Fab classification of Leukemia. 
 
 
 
Even if clinically useful, the FAB classification system has one major limit, it does not 
take into account many factors that are now known to affect prognosis.  
For these reasons, in 2008 the World Health Organization (WHO) classified AML by the 
presence of recurrent chromosomal rearrangements, which have significant prognostic 
values (Table 2). Indeed, based on their cytogenetic features, AML patients can be broadly 
classified into three risk groups according to their response to standard therapy: favourable 
risk for patients harbouring t(15;17), t(8;21) and inv(16); intermediate risk for patients with 
normal karyotype (NK) or t(9;11); adverse risk for patients with complex karyotype 
(harbouring 3 or more abnormalities), del(7), del(5), inv(3)/t(3;3)21. 
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Table 2. WHO classification of Leukemia. 
 
 
Despite intensive search for new therapies and prognostic markers, AML is still a disease 
characterized by highly variable prognosis among patients and high mortality rate. Indeed, 
the overall survival rate (OS) of adult AML patients at 5 years is less than 50% and, in the 
“oldest people” only 20% survive two years22. The gold-standard treatment of AMLs, 
independently from their clinical and morphological classification, is based on 
chemotherapy, consisting of an induction therapy with 3 days of anthracycline and 7 days 
of cytarabine (“3+7”, or approaches of similar intensity), followed by diversified 
consolidation strategies. Standard treatments induce complete remission (CR) in up to 80% 
of AML patients. However, ~70% of them relapse within 5 years, and eventually succumb 
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to the disease23. The relapse of AML is thought to result from residual chemoresistant 
leukemic cells still present at CR, although below the limits of detection of conventional 
morphologic and molecular assessments.  
An exception to this situation are the myeloid leukemias harbouring the t(15;17), defined 
as APLs, that results in expression of the fusion protein PML-RAR, for which the standard 
treatment is based on a differentiation therapy induced by trans-retinoic acid (ATRA). This 
is one of the first examples of differentiation therapy developed following the dissection 
and unravelling of the molecular functions of the product that derives from the fusion of 
the gene coding for the promyelocytic protein (PML) with the retinoic acid receptor-alpha 
(RARa). The fusion product blocks the activity of the PML protein by recruitment of co-
repressors and histone deacetylases that prevent transcription of genes involved in cellular 
differentiation and, therefore, block the cells in an immature state. Pharmacological doses 
of ATRA can bind the RARa component of the fusion product, inducing its degradation by 
ubiquitinization. This allows for the normal functions of PML,  promoting granule 
formation and differentiation of the promyelocytes24. 
In this example, specific inhibition of the genetically altered activation molecules of the 
leukemic cells allows the leukemic cells to differentiate and die. Because acute myeloid 
leukemias usually have mutations of more than one gene, combinations of specific 
inhibitors that act on the effects of different specific genetic lesions promises to result in 
more effective and permanent treatment. However, we still need to clarify the 
leukemogenic process and to identify the genetic lesions and molecular mechanisms that 
contribute to the development of AML in order to be able to carry out a more accurate risk 
stratification of newly diagnosed patients and to identify critical targets for the design of 
patient-specific treatments.  
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1.5 Multiple hit model of AML 
AML is a multistep disease. The primary lesions are necessary but not sufficient for the 
full development of disease, which is observed only following the acquisition of 
cooperative mutational events25. This principle has been demonstrated in mouse models, 
where introduction of the fusion gene found in acute leukemia by transgenic technology or 
retroviral transduction results in predisposition to acute leukemia with long latency, unless 
the accumulation of additional genetic hits is facilitated by treatment with a mutagenic 
agent. This multistep carcinogenesis induces cancer cells to acquire all the properties in 
order to become malignant: sustaining proliferative signaling, evading growth suppression, 
enabling replicative immortality, resisting cell death, inducing angiogenesis, activating 
invasion and metastasis, avoiding immune destruction, and deregulating cellular 
energetics26. 
It has been proposed that this multistep process requires the synergy and the cooperation of 
two classes of mutations: class I mutations that activate signal transduction pathways and 
confer a proliferation advantage on hematopoietic cells, and class II mutations that affect 
transcription factors and primarily serve to impair hematopoietic differentiation27-29 (Figure 
3). 
 
Figure 3. Multiple hit model in AML. According to this theory two classes of mutations 
are needed. Class I mutations affect genes that are involved in signal transduction and lead 
to increased cell proliferation and/or survival and class II mutations that impair 
differentiation30. 
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The class I mutations can increase proliferation and survival potential of both 
hematopoietic stem and progenitor cells, often leading the constitutive activation of protein 
tyrosine kinases (PTKs) normally without involving cellular differentiation. Class I 
mutation can lead both to gain-of-function or loss-of-function of the protein. Examples of 
proteins constitutively activated by gain-of-function mutations are: ABL, JAK2, FLT3, 
PDGFR, KIT and activating mutation of the RAS family members25,31-34, while, examples 
of proteins that lose their activity by loss-of-function alterations are NF1 or PTPN1135,36.  
The class II mutations affect differentiation and are able to increase self-renewal properties 
of hematopoietic cells. This kind of mutation usually can works on chromatin architecture, 
recruiting either co-activator or repressor complexes, while having modest roles on cell 
proliferation or survival. Examples of this class of mutations comprise gene 
rearrangements that act modifying transcriptional regulation on target such as the core-
binding factor CBF, CEBP, RAR, and MLL37,38, and components of the transcriptional 
activation complex such as CBP, MOZ, and TIF239, which play a crucial role during the 
differentiation of hematopoietic stem and progenitor cells. Are considered Class II 
mutations all the chromosomal aberrations such as t(8; 21), inv(16) and t(15; 17), which 
generate fusion transcripts of RUNX1/ETO, CBFβ/MYH11 and PML/RARα27, 
respectively. 
Not only chromosomal abnormalities but also mutations of the transcription factors 
RUNX1, C/EBPα and MLL are classified into this group27.  
The multiple hit model is supported by several clinical and experimental data and 
mutations from different complementation groups were frequently found in the same 
patient. Recent studies and technologies, in fact, demonstrates that in leukemic cells more 
than one recurring mutations is present, suggesting, once again, a multi-hit model for 
leukemogenesis40. Studies on fusion genes MLL/AF4 or TEL/AML1 have shown that, 
although some class II mutations arise in utero, the development of frank leukemia occurs 
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with a protracted postnatal latency, indicating the need of additional secondary genetic 
alteration41.  
In the acute promyelocytic leukemia (APL), characterized by the t(15;17) rearrangement,  
it has been observed that 30% of the patients also harbor a FLT3 activating mutation, 
suggesting a possible cooperation between these two mutations in inducing APL42. This 
hypothesis has been confirmed in an experimental animal model of APL that provided 
strong evidence for functional cooperation between the PML/RAR fusion and the 
activating FLT3 mutation. Briefly, the expression of PML/RAR from the cathepsin G 
promoter in transgenic mice resulted in an APL-like disease with 6 months latency and 
incomplete penetrance of ~15%–30%43. Co-expression of the FLT3-ITD mutation in the 
bone marrow of PML/RAR transgenic mice induced APL with a shorter latency and 
complete penetrance42. In particular, FLT3 mutations are considered the "ideal" second hit 
cooperative mutations as shown in different animal models of AML44,45.  
1.6 Clonal evolution of Leukemia 
Clonal evolution and subclonal diversity are hallmarks of the pathophysiologic 
mechanisms of many cancers including Acute myeloid Leukemia. A successive acquisition 
of the multiple cancer hallmarks depends on a succession of alterations in the genomes of 
neoplastic cells and dominates the clonal evolution. This clonal selection is an evolutionary 
process that is driven by selection and expansion of adapted subclones that acquire 
proliferative advantage compared with the others46. The clonal evolution model of cancer 
development involves gain of function of oncogenes and loss of function of tumor 
suppressor genes that cooperate to induce fulminant disease.  
 This intratumoral genetic heterogeneity has been initially provided by various techniques: 
chromosome karyotyping47, genetic analysis of multifocal cancers27, fluorescence in situ 
hybridization (FISH)-based tissue section screening48, immunophenotype-based cell 
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analysis49, molecular probing of multiple small biopsies, microselected tissues, and sector 
ploidy profiling50.  
Recent techniques, such as next generation deep parallel sequencing (NGS) and copy 
number alteration (CNA) analysis have provided an important improvement in the 
understanding of subclonal tumor composition and evolution leading to the definition of 
driver and passenger mutations. Not all the mutation, in fact, contribute equally to tumor 
evolution.  The mutation that  confer a selective growth advantage and promote clonal 
expansion are definited driver mutation. The passenger mutation, instead, are inert 
mutation and are found within cancer genomes because somatic mutations without 
functional consequences can occur during cell division. These inert mutations, will 
propagate through the clonal expansion of tumor and will be present in all cells of the final 
tumor.  
All these recent data have provided strong evidences supporting  the concept that tumors 
diplsay an intrinsic genetic landscape with an highly subclonal heterogeneity and 
intraclonal genetic diversity 51,52. Moreover, in some types of tumor, such us breast or 
pancreatic cancer, the degree of genetic diversification has been linked with poorer 
prognosis53,54.  
In AML, it has been shown that each patient contains different leukemic subclones that 
evolve along a complex, branching multi-clonal evolution. In these cases, a shift in clonal 
dominance can occur and minor clones might become able to outcompete dominant 
clones55-57. Clonal evolution of leukaemia could be described in two principal ways: linear 
or branched.  The first case is represented by an essentially linear architecture with 
stepwise accumulation of driver mutations (Figure 4). Observing the mutational 
complexity, by deep sequencing methods, it was possible to show that during the 
development of cancers, including AML, dominance of subclones can change throughout 
the course of disease54,55,57-60, and the clones that contain the highest numbers of lesions are 
not necessarily numerically dominant within the tumour40,55,56. 
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Even if cancers can be traced back to a single cell, the continuous acquisition of lesions 
dramatically increases genetic and clonal heterogeneity. For these reasons it is likely that 
most cancers evolve with a complex branching architecture (Figure 4). 
 
 
Figure 4. Linear and branching clonal evolution. (A) Linear evolution. The dominant 
clones are the results of stepwise accumulation of driver mutation. In this manner the final 
tumor contains all the mutaions acquired during the evolution of desease. (B) Branching 
evolution. The final composition of leukemia is composed from several clones, each of 
which contain its subset of specific driver mutation.  
 
Even if the evolution of cancer occurs through a complex branching pattern of mutation 
acquisition61, there are evidences that both linear and branched architecture can be present 
in individual AMLs. A study on 8 primary and relapsed AML samples shows that in some 
cases (3/8), only a single mutation cluster was found in the primary tumour. In these cases, 
the single clone gained additional mutations at relapse, consistent with a linear pattern of 
evolution, although minor branching subclones could have been missed (Figure 4). In the 
remaining case (5/8), multiple mutation clusters corresponding to different subclones were 
detected in the primary sample57 ( Figure 5A).  
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Other two studies confirmed that re-emergence or evolution of a founder or ancestral clone 
is typical in relapsed AML62,63. 
 
 
Figure 5. Representation of clonal evolution from the primary tumour to relapse. A) 
The founding clone in the primary leukemia contain all the somatic mutations that are 
recurrent in all AML cells: one subclone within the founding clone evolved to become the 
dominant clone at relapse by acquiring additional mutations. b, Examples of the two major 
patterns of tumour evolution in AML. Model 1 shows the dominant clone in the primary 
tumour evolving into the relapse clone by gaining relapse-specific mutations; Model 2 
shows a minor clone carrying the vast majority of the primary tumour mutations survived 
and expanded at relapse57.  
 
1.7 Chemo-resistance  
The mechanisms of chemo-resistance of AMLs are currently unknown, however, by 
whole-genome sequencing of primary/relapse tumor pairs, the relapse-specific mutations 
have been demostrated. These mutations were detectable in the primary tumors only in 
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some of the patients analysed. A central open question in cancer treatment is what is the 
precise nature of the interaction of clonal evolution with cancer therapy.  
Initial studies explained the presence of relapse-specific mutation with the potential 
mutagenic role of chemotherapy (Figure 6A). Studies of WGS (whole genome sequencing) 
on Acute myeloid malignancies have suggested that the novel mutagenesis may result from 
the genotoxic effects of chemotherapy. This observation was supported also by a changing 
spectrum of somatic single-nucleotide alterations64. A different situation has been shown in 
the case of Chronic Lymphoid Leukemia (CLL), where the contribution of the 
chemotherapy’s mutagenizing effect seems to be limited65. Therefore, although 
chemotherapy-induced mutagenesis has the potential to contribute to further clonal 
diversification, other sources for generating evolutionary shifts appear to be at play, and 
probably involve pre-existing genetic variants or subclones57. As shown in Figure 6 two 
models have been proposed to explain chemoresistance and AML relapse: i) in the first 
model proposed, the chemoterapy can induce novel mutagenesis that confer resistance to a 
clone that became dominant (Figure 6A). ii) a minor resistant leukemic clone survive to 
chemotherapy and expand at relapse (Figure 6B). In this model the selection and expansion 
of resistant clones is induced by the selective pressure of therapy that is often directed at a 
particular genetic context which may not be shared by all subclones. In this case, no new 
mutation occurs, but a minor clone already contain all the features that confer 
resistance57,64. 
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Figure 6. Two models of how cancer therapy may accelerate clonal evolution. a) in the 
first model, cancer therapy containing genotoxic agents can induce novel mutagenesis 
leading to resistance. b) in the second model, no new mutations are acquired but therapy 
can accelerate clonal evolution by selecting a clone that already contain a mutation that 
confers the resistance to the therapeutic agent64. 
 
1.8 Leukemia Xenograft model	  
 
Even the most clinically aggressive sample of leukemia cells from a patient is unlikely to 
grow when placed in culture, and cell characteristics can change depending on the media 
used66-68. Additionally, culture systems cannot replicate the interactions between the 
leukemia cells and their stroma and immune cells. In other words, it is impossible to 
reproduce in vitro the niche where the leukemic cells growth and expand. To circumvent 
these limitations, murine xenograft models have been developed to allow engraftment of 
primary patient samples66. Xenografts in immunodeficient mice allow performing 
functional studies on patient-derived AML cells69. The mouse is frequently used as a 
model due to its relative physiologic similarity to humans and its capacity for facile genetic 
manipulation, as well as because of the relative efficiency of breeding and housing mice70. 
Although xenograft models have been extensively used in leukemia studies, there are some 
disadvantages and limitations to the utility of these models. For instance, the abbreviated 
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life span, increased metabolic rate, and altered telomere length of inbred mouse strains, as 
well as the altered prevalence and time of onset of cancers are examples of some 
fundamental physiological differences between humans and mice71. In particular, if the 
immunodeficiency is a prerequisite for preventing human tumor cell rejection, in xenograft 
models the growth of tumor occurs in a host with an impaired immune system. 
Engraftment of patient-derived cells in immuno-compromised mice has been established in 
the early 1990s using severe combined immunodeficiency (scid) mice. Engraftment 
capacity has improved by using more severely immuno-compromised mice72-74. We 
currently use the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse model. These mice 
combine the features of the NOD background (that spontaneously develops type 1 
diabetes), the severe combined immune deficiency mutation (scid) and IL2 receptor 
gamma chain deficiency resulting in multiple defects in both the innate and the adaptive 
immune system (lacking B, T, and functional NK cells)75-79. Moreover, impaired NK 
function reduced the need for conditioning with radiation prior to leukemia 
administration80-82. This was of importance, since these mice have a tendency to develop 
spontaneous thymic lymphoma, and have generally a short life span83. In NSG mice, 
engraftment can occur very fast, it is possible to detect blasts in the peripheral blood, and 
total number of cells required to engraft can be little75. NSG mice can even be engrafted 
with as little as 1–100 cells derived from leukemic patients84. The relative simplicity of 
engrafting human leukemia in these mice made the NSG model excellent for leukemia 
research. 
 
1.9 shRNA screening 
RNA interference (RNAi) facilitates the assessment of gene function by silencing gene 
expression. It exploits a physiological mechanism that represses gene expression, primarily 
by causing the degradation of mRNA transcripts. In mammalian cells, physiological RNAi 
is primarily mediated by non-protein-coding RNA transcripts, known as microRNAs 
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(miRNAs). miRNAs are produced in a similar manner to mRNAs, but are processed into 
shorter RNA species containing a hairpin structure, known as short-hairpin RNAs 
(shRNAs). shRNAs are, in turn, processed into short double-stranded pieces of RNA 
known as short interfering RNAs (siRNAs). Within the multi-protein RNA-induced 
silencing complex (RISC), one strand of a siRNA duplex binds a protein-coding mRNA 
transcript that bears a complementary nucleotide sequence. This interaction allows a 
nuclease in the RISC to cleave and destroy the protein-coding mRNA, therefore silencing 
the expression of the gene in a relatively sequence-specific manner 85. Recently, the use of 
libraries of shRNAs, based on miRNAs design and cloned in lentiviral vectors, has been 
shown to be an effective way to perform both in vitro and in vivo screenings. In particular, 
this approach in vivo has led to the identification of genes involved in the cancerogenesis 
of some cancer types. An shRNA screening performed in a lymphoma murine model has 
defined a central role for regulators of actin dynamics and cell motility in lymphoma cell 
homeostasis impairing lymphoma cell migration to the lymph nodes and other organs that 
represent common sites of lymphoid metastasis. Validation experiments confirmed that 
these proteins represent a bona fide lymphoma drug targets86. In a mouse model of 
hepatocellular carcinomas a library of pools of shRNAs targeting the mouse orthologs of 
genes re-currently deleted in a series of human hepatocellular carcinomas has proved their 
contribution to tumor progression..  Among them, it has been shown that XPO4 encodes a 
nuclear export protein whose substrate, EIF5A2, is amplified in human tumors and is 
required for proliferation of XPO4-deficient tumor cells and for the promotion of 
hepatocellular carcinoma in mice87. More recently, both Mllt6 and b-catenin have been 
identified as top oncogenic screen hits in a model of HrasG12V epidermal hyperplasia and 
have been shown to play an important role in tumour initiation and maintenance of human 
squamous cell carcinomas in xenograft models88. Concerning AML, up to date, similar 
screenings have been conducted only on an AML mouse model driven by MLL-AF9 and 
NrasG12D. Several shRNAs targeting Brd4, a member of the BET family of bromodomain-
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containing proteins, were among the most strongly depleted, identifying this gene as the 
top scorer in the screen. These proteins bind to acetylated histones to influence 
transcription. Knock down or pharmacological inhibition by JQ1 of BRD4 had a profound 
effect on AML progression in vivo in mice transplanted with MLL-AF9/NrasG12D 
leukaemia cells. A similar effect was observed on the growth of human AML cell lines 
harboring a variety of mutations besides MLL-AF989. Furthermore, gene expression 
changes upon BRD4 inhibition were similar to those described by the same researchers 
upon knock down of Myb in the same AML mouse model. Ablation of Myb expression 
inhibited the proliferation of leukemic cells in vitro and eradicated disease in vivo with 
limited effects on normal hematopoietic cells. Thus, in murine model of AML, Myb 
appears to be an early and key player in the oncogene addiction mediated by MLL- fusion 
proteins90,91 . These data suggest that there are common and overlapping pathways 
mediating self-renewal downstream of a variety of different initiating mutations that can be 
identified performing estensive shRNA screenings on AML characterized by different 
molecular alterations.  
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2 AIM OF THE PROJECT 
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AMLs are haematological disorders characterized by the accumulation of a large number 
of cells blocked at immature stages of differentiation. It has been shown that AMLs are 
extremely heterogeneous in terms of frequency and origin of cancer stem cells (also called 
leukemia-initiating cells, LICs). Moreover, AMLs are multi-clonal diseases in which each 
subclone seems to evolve along a complex and branching multiclonal process. These 
observations may have important implications for AML treatment.  In spite intensive 
research for new therapies and prognostic markers and the discovery of many cancer genes 
which are potentially druggable, AML is still a disease with a highly variable prognosis 
among patients and a high mortality rate92. Indeed, the overall survival rate (OS) of adult 
patients at 5 years is less than 50% and, in the oldest people only 20% survive two years22. 
The relapse is very likely due to the inefficacy of the therapies to target the LICs that, after 
the first remission, are able to reinitiate the disease. Therefore, it is becoming increasingly 
evident that many open questions remain about the leukemogenic process and, in most 
cases, a reliable treatment is still lacking. This is very likely due to the extreme genetic and 
biological complexity of AMLs, that appear as intrinsic limits to the generation of valid 
anti-leukemia targeting drugs. Thus, we need new studies that will allow us to understand 
how blasts grow and evolve during leukemia development and in response to therapies, 
and to identify appropriate druggable targets for the eradication of the LICs. 
Along this line, our study has three main goals: 1) the identification of LICs number 
through the transplantation of traceable leukemic cells; 2) the study of the clonal evolution 
of the disease in vivo before and after chemotherapy treatment; 3) the identification of gene 
products involved in maintenance and growth of leukemic blasts and assessment of their 
usage as novel therapeutic targets. For all aims, our experimental approach is based on the 
infection of leukemic blasts, both of murine and human origin, with lentiviral libraries and 
their transplantation in recipient animals. 
In order to identify and track each LIC in vivo, we planned to couple high-throughput 
sequencing to viral genetic barcoding, transducing the leukemic blasts with a 30 milion-
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barcodes lentiviral library. The incorporation of the barcodes into the genome of the 
infected cells allows to univocally identify the progeny of each LIC and to follow their 
destiny after in vivo growth.  This technique has many important advantages. It allows 
transplantation of a mixed population and tracking of the cells in their physiological 
environment. Indeed, it minimizes in vitro manipulation, sorting, and transplantation in 
limiting dilution that can stress the cells causing depletion of the number of LICs and 
decrease in their leukemogenic potential. It has an increased sensitivity because it allows 
single cell identification by detection of individual barcodes. Moreover, because it does not 
rely on restriction digestions, it avoids the problem of differential amplification of 
fragments with varying lengths or melting temperatures. Therefore, this is an unbiased and 
quantitative method that provides accurate information about the proportionality of the 
clones deriving from different LICs. Indeed, based on the number and the relative 
distribution of barcodes, it allows establishing the number of LICs and their relative 
contribution to tumor development93.  
In order to identify genes that could be used as therapeutical and druggable targets required 
for the onset and maintenance of AML, we performed a large-scale in vivo shRNA 
screening on the human AML samples available. By comparing the composition of the 
shRNAs present in the preinjection pool of cells to the one retrieved following tumour 
development in vivo and by measuring their relative abundance (calculated as the ratio 
between the number of reads at tumour development divided by the number of reads in the 
preinjection pool) we will able to define which shRNAs have been enriched and which 
have been depleted during tumour growth. After tumor development in vivo, the positive-
selected shRNAs should allow the identification of tumour suppressor genes and the 
counterselected shRNAs should allow the identification of oncogenes required for AML 
development. 
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3.1 Buffers 
•   PBS 1X: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, pH=7.4; 
•   Red Blood Cell (RBC) Lysis Buffer: 8.125 mg/mL NH4Cl, 1 mg/mL KHCO3, 0.13 
mM EDTA; 
•   Luria Broth (LB): 2.5g Luria Broth/L 
•   Terrific Broth (TB): 4.7g Terrific Broth/L 
•   Annealing buffer 2X: 200 mM CH3COOK, 60 mM HEPES-KOH, 4 mM Mg-
acetate 
•   2X HBS: 50 mM HEPES pH7.1, 280 mM NaCl, 1.5 mM Na2HPO4 
•   TAE (Tris-Acetate-EDTA, 50x): 242 g/l Tris base, 57.1 ml/l glacial acetic acid 
(37.5%), 18.6 g/l EDTA. 
 
3.2 Mammalian cell culture 
All cells were maintained at 37°C, 5% CO2 and 20% O2. 
Phoenix 293T cells were cultured in DMEM, supplemented with 10% Foetal Bovine 
Serum (FBS, South American), 100 U/mL Penicillin, 100 U/mL Streptomicin, 2 mM L-
Glutamine; 
NB4 cells were cultured in RPMI, 10% Foetal Bovine Serum (FBS, South American), 100 
U/mL Penicillin, 100 U/mL Streptomicin, 2mM L-Glutamine; 
AML samples were cultured in RPMI, 20% Foetal Bovine Serum (FBS, North American), 
2 mM L-Glutamine, 1% 5637-conditioned supernatant. 
 
3.3 Xenografts of human AMLs 
Since human acute myeloid leukemia (hAML) xenotransplanted in immunocompromised 
animals retain the phenotypic characteristics of the original sample, we established some 
xenografts of hAMLs. We took advantage of the humanized mouse models generated by 
engraftment of immunodeficient mice with components of the human immune system, the 
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NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunocompromised mice, as the host. NSG 
mice have been shown to support greater engraftment of human hematopoietic stem cells 
(hCD34+ cells) than all other strains75. 
Bone marrow or peripheral blood mononuclear cells freshly collected from AML patients 
are CD3-depleted using the CD3 MicroBeads kit from Milteny Biotech. The patients 
enrolled in the study gave written informed consent. The human samples are characterized 
for their karyotype and, by Sanger sequencing, for two of the most recurrent mutations in 
AMLs: mutations in FLT3 and in NPM1.  
Our xenotransplantation protocol consists in the intravenous injection from 5 x 105 to 12.5 
x 106 cells of CD3-depleted mononuclear cells freshly collected from the AML patients in 
6-8 weeks old NSG mice. Our rate of success is around 70%.  
The level of engraftment of the human blasts in the transplanted animals is determined by 
FACS analysis of the peripheral blood (PB) cells stained with antibody specific for the 
human CD45 hematopoietic surface antigen (hCD45) and according to the protocol 
described in the section 3.11. 
 
3.4 Animal Studies 
The PML-RAR knock-in mice were provided by T.J. Ley43  and backcrossed in the 
C57BL/6J background. This model expresses the fusion protein PML-RAR in early 
myeloid cells under the control of human cathepsin G regulatory sequences. Acute 
promyelocytic leukemias develop spontaneously in this KI model in ~70% of animals 
between 6 and 16 months of age (average latency of ~1 year) 43.  
All mice used in the study for transplantation of the leukemic blasts were purchased from 
Charles River: C57BL6/Ly5.2 (strain C57BL/6NCrl), C57BL6/Ly5.1 (strain B6.SJL-
PtprcaPepcb/BoyCrl), NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG). The NSG is the 
most immunodeficient mouse strain94. NSG mice lack mature T cells, B cells, and natural 
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killer (NK) cells83. This model preserves microenvironment during long-term 
engraftment95 allowing the study of primary human tumor.  
 
3.5 Vectors 
•   pRSI16cb-U6-13kCB18-13kCB18-HTS6-UbiC-TagRFP-2A-Puro: Lentiviral 
vector that contains two barcodes of 18bp cloned under the promoter U6. The vector 
contains genes that encode for puromycin and ampicillin resistance and the reporter 
gene TagRFP. Puromycin resistance and TagRFP are constitutively expressed under 
the control of UbiC promoter. This vector was used in the clonal tracking experiments 
(Figure 7). 
	  
Figure 7. Map of the lentiviral vector used for the clonal tracking experiments: 
pRSI16cb-U6-13kCB18-13kCB18-HTS6-UbiC-TagRFP-2A-Puro.  
 
•   pRSI17cb-U6-sh-13kCB18-HTS6-UbiC-TagGFP2-2A-Puro: Lentiviral vector that 
allows constitutive expression of the shRNAs under the U6 promoter. To each shRNA 
is associated a unique barcode of 22 bp and a variable number (up to 13,000 possible 
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combinations) of clonal tracking barcodes of 18 bp. Differently from the clonal 
tracking vector, it expresses the TagGFP reporter gene. This vector was used in the 
shRNA screening experiments (Figure 8).  
	  
Figure 8. Map of the lentiviral vector used for the shRNA screening: pRSI17cb-U6-sh-
13kCB18-HTS6-UbiC-TagGFP2-2A-Puro.  
 
•   pINDUCER11 (miR-RUG): inducible lentiviral vector that expresses constitutively 
rtTA3 and eGFP under the hUBc promoter. Doxycycline (dox) administration allows 
the expression of TagRFP and shRNAs, cloned under a tetracycline dependent 
promoter TRES2 (tetracycline response element 2). This vector was used for 
validation of the target shRNAs identified by our screening (Figure 9).  
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Figure 9. Map of the pINDUCER11 (miR-RUG) inducible vector. 
 
3.6 Lentiviral packaging vector  
•   pMDLg/pRRE: packaging lentiviral vector derived from HIV-1. It express for HIV-1 
genes gag and pol. In general, all the vector HIV-1-derived are deficient for all the 
genes (vif, vpu, vpr  nef) that contribute to viral pathogenicity. Is used in lentiviral 
production with packaging vector of 3rd generation in combination with pRSV-Rev 
and pMD2.VSVG. 
•   pRSV-Rev: packaging lentiviral vector that express for HIV-1 Rev shuttle protein. 
Rev, in fact, allows to viral pre-mRNA to be carry out from the nucleus.  It is used in 
lentiviral production with packaging vector of 3rd generation in combination with 
pMDLg/pRRE e pMD2.VSVG. 
•   pMD2.VSVG: envelope vector derived from Vescicular Stomatitis Virus. It is used to 
pseudotype viral particles with VSV-G proteins in lentiviral production with 
packaging vector of 2nd and 3rd generations.  
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•   pCMVR8.2: packaging lentiviral vector HIV-1-derived. It expresses the genes gag, 
pol, rev, and tat for HIV. It is used in lentiviral production with packaging vector of 
2nd generation in combination with pMD2.VSVG. 
 
3.7 Lentiviral libraries 
 
3.7.1 Clonal tracking Library 
For the clonal tracking experiments, we purchased from Cellecta a lentiviral library 
containing exclusively two consecutive 18-nucleotide barcodes cloned after the U6 
promoter. Because there is a combination of 13000x13000 different 18-nucleotides 
barcodes, the complexity of the clonal tracking libraries is of around 30x106 unique 
barcodes. The lentiviral expression vector described in section 3.5 contains also a 
puromycin-resistance gene (PuroR) and a red fluorescent protein marker (TagRFP) under 
control of UbiC promoter. 
3.7.2 shRNA screening Library 
The shRNA library used in our scrrening was purchased from Cellecta. The library is 
custom made and contains 1204 shRNAs targeting 118 genes (10 shRNAs per gene) 
involved in epigenetic regulations. The lentiviral expression vector, described in detail in 
setion 3.5, contains also a puromycin-resistance gene (PuroR) and a green fluorescent 
protein marker (TagRFP). The shRNAs are expressed under the U6 constitutive promoter 
and are linked to a unique 18-bp barcode that univocally identifies each shRNA and can be 
amplified by PCR. Moreover, each shRNA is cloned in a library of vector backbones that 
contains a second barcode of 18 nucleotides. There are up to 12415 different combinations 
per shRNA of these second barcodes. This characteristic allows for clonal identification of 
the cells targeted by each shRNA. 
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3.8 Production of the lentiviral particles 
Packaging of the lentiviral vectors was performed using 2nd or 3rd generation packaging 
vectors with two alternative methods of transient transfection: calcium phosphate 
(Ca3(PO4)2) or Lipofectamine®. All transfections were performed using 293T cells plated 
in 15-cm plates.  
 
3.8.1 Transfection with calcium phosphate  
22µg of lentiviral plasmids were mixed with 9µg of envelope plasmid pMD2.VSVG and 
with 2nd (13µg of pCMVR8.2) or 3rd (5,5µg pRSV-Rev and 11µg of pMDLg/pRRE) 
generation packaging vectors. CaCl2 is added to the vectors mix at a final concentration of 
0.5 M. This mixture is, then, added drop-wise to bubbling 2X HBS solution. After an 
incubation of 20 minutes, the DNA precipitates are slowly added to the 293T cells 
monolayer (cells should be 70-80% confluent). Lentiviral supernatants are harvested 24 
and 48 hours after transfection. After centrifugation at 2500 rpm for 5 minutes at RT and 
filtering through 0,2 µm filter (Nalgene Rapid-Flow), the lentiviral particles are 
concentrated 1000-fold by ultracentrifuging at 75,000 x g for 2 hours at 16°C with 
OptimaTM L-90K Ultracentrifuge (Bechman Coulter) and stored at -80°C96. 
 
3.8.2 Transfection with Lipofectamine® (Invitrogen) 
 
We prepare two solutions. In the first solution, 6 µg of lentiviral plasmid of interest, 7 µg 
of pMD2.VSVG vector, 24 µg of pCMVR8.2 vector, 60  µl of  PlusTM Reagent are mixed 
in 1.2 ml of DMEM without FBS and antibiotics. In the second solution, 90 µl of  
LipofectamineTM are added to 1.2 ml of DMEM without FBS and antibiotics. Both 
solutions are first incubated separately for 15 min and then mixed together. After a further 
incubation of 15 minutes, the DNA-lipid complexes are slowly added to the 293T cells 
monolayer (cells should be 70-80% confluent). Collection and concentration of the viral 
supernatants follow the same protocol described in transfection with calcium phosphate.  
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3.9 Titration of the lentiviral vectors 
The titer of the lentiviral preparations can be determined from a serial dilution of the 
lentiviral stocks by flow cytometry (FACS) or by quantitative PCR (qPCR). The qPCR 
allows also to measure the number of integrated lentiviral particles in the genome of the 
transduced cells. We followed the protocols described in Barde et al, 201096  
 
3.9.1 Titration by FACS 
The titration of the production of lentiviral particles is carried out, using 293T cells. 
250,000 cells/well are plated in a 12 -well plate in 0.5 mL of medium. We carry out a serial 
dilution (dilution factor 1:10) of the initial viral stock, starting from a dilution of 10-1 up to 
a dilution of 10-5. With 10 µl for each dilution we infect two wells of cells. 72 hours post-
infection the cells are collected, fixed in a 1% formaldehyde solution and analysed by 
FACS for the percentage of TagRFP- or GFP-positive cells (Becton Dickinson LSRII). 
The multiplicity of infection (MOI) and titer, reported as transducing units per ml (TU/ml), 
is determined using the following equation:  
 
𝑡𝑖𝑡𝑒𝑟	  ( 𝑈µμL) = Number	  of	  target	  cells	  (count	  at	  day	  1) ∗ [%	  𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒	  𝑐𝑒𝑙𝑙𝑠100 ]𝑣𝑜𝑙𝑢𝑚𝑒	  𝑜𝑓	  𝑣𝑒𝑐𝑡𝑜𝑟	  (𝑚𝑙)  
 
3.9.2 Titration by qPCR 
In order to perform the titration by qPCR, before extraction of the DNA, the cells infected 
with dilution of the lentiviral stock as described above, are usually kept in culture for at 
least 96 hours in order to reduce the contamination from the not integrated plasmid. The 
viral copy number per cell is determined by qPCR amplification of a genomic sequence, 
present in two copies per genome (i.e. Albumin, Alb), in parallel with viral sequences 
present in the lentiviral vectors and integrated in the target cells (GAG or WPRE).  The 
Alb genomic sequence is also cloned in the same lentiviral backbone to prepare a standard 
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curve, used as a reference to count the number of molecules present in the samples. Each 
sample is amplified using both the Alb and the GAG or the WPRE primers. After 
amplification the samples are analysed using SDS software (Applied Biosystems) that 
allows calculation of the standard curve and determination of the GAG or WPRE and Alb 
quantity for each sample. The copy number per cell for each sample is calculated 
according to the following formula: 
𝑉𝑒𝑐𝑡𝑜𝑟	  𝑐𝑜𝑝𝑦	  𝑛𝑢𝑚𝑏𝑒𝑟 = 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦	  𝑚𝑒𝑎𝑛	  𝑜𝑓	  𝑊𝑃𝑅𝐸	  𝑜𝑟	  𝐺𝑎𝑔	  𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦	  𝑚𝑒𝑎𝑛	  𝑜𝑓	  𝐴𝑙𝑏	  𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ∗ 2 
The sequences of the primers used for the qPCR are listed in Table 3:  
Table 3. Primers used for qPCR 
 
 
3.10 Transduction of the leukemic blasts 
Leukemic blasts (1 x 106 cells per well) are seeded in Retronectin-coated (Takara Bio) 24-
well plates (40-60 µg/ml per well).  The leukemic cells are transducted using a multiplicity 
of infection (MOI) of 2, in 1 ml of medium containing 8 mg/ml polybrene. Transduction is 
performed by spinoculation at 2300 rpm for 90 min at 32-37°C and incubation at 37°C for 
2 hrs. Since the polybrene can be toxic for the cells, after this period of time, the infection 
medium is replaced with fresh medium and the cells are incubated for 24 hours at 37°C. 
After this incubation, half of the sample is used for transplantation into recipient mice and 
the other half is used to extract directly the DNA to be used as reference of infection at 
time of transplantation.  
 
   50 
3.11 Measurment of the level of engrafment of hAML blasts by FACS analysis 
The level of engrafment of the human leukemic cells in the transplanted animals is 
measured by FACS analysis of 20 µl Peripheral Blood cells stained with antibody specific 
for the human CD45 hematopoietic surface antigen (hCD45) APC conjugated (Miltenyi 
Biotec). For the staining, the plasma is removed by centrifugation at 2000 rpm. After 
blocking in 50 µL of 10% BSA in PBS 1X at 4°C for 30 min, the samples are resuspended 
in 50 µL di PBS 1X containing the specific antibody with a dilution 1:100. After 1-hour 
incubation at RT, the red blood cells are lysed in RBC Lysis Buffer (8.125mg/mL NH4Cl, 
1mg/mL KHCO3, 0.13mM EDTA) for 10 min on ice. After 2 washing cycles, the cells are 
fixed in 1% FA (Formaldehyde, Sigma Aldrich) and analysed by FACS. The level of 
engraftment of leukemia in the host animals is determined as percentage of hCD45+ cells. 
The recipient mice are sacrificed when the percentage of hCD45+ is >60%. Bone marrow 
and spleen are collected and the purified blasts are frozen in 10% dimethyl sulfoxide 
(DMSO) in FBS and stored in liquid nitrogen.  
 
3.12 Preparation of spike-in control cells 
To prepare the spike-in controls, we selected 5 independent clones from a  clonal tracking 
library containing 13,000 different barcodes (Cellecta). This library is similar to the 30 
million clonal tracking library but contains a single barcode of 18 bp. Because the barcode 
is cloned in the same vector of the clonal tracking library, they can be amplified with the 
same PCR strategy described for the library in section 3.14. The list of the sequences of the 
5 barcodes used as spike-in controls is given in Table 4.  
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Table 4. Barcodes sequences used for Spike in Experiment. 
 
 
 
The 5 single clones were selected by bacterial transformation and isolation of single 
colonies. The bacterial colonies were grown for purification of the DNA by maxipreps. 
The DNA was used to make high-titer lentivirus (as described in section 3.8). 
NB4 cells were infected at low MOI with each clone independently. We obtained a 
percentage of infection between 5 and 10%. The infected NB4 cells were, then, selected in 
1µg/ml puromicyn for 48 hrs in order to obtain a pure population of cells with only one 
barcode  per cell. 
By serial dilution, we prepared 5 spike-in controls, that were combined with samples of 
blasts from which the barcode libraries were amplified for HTS: 
-   10 NB4 cells with clone A 
-   100 NB4 cells with clone B 
-   1,000 NB4 cells with clone C 
-   10,000 NB4 cells with clone D 
-   50,000 NB4 cells with clone E 
 
3.13 Genomic DNA extraction for amplification and sequencing of the barcodes  
Identification of the barcodes in the experimental samples requires amplification of the 
integrated lentiviral constructs from the genomic DNA of the leukemic samples. 
Subsequent high-throughput sequencing of the amplified barcodes by the Illumina HiSeq 
2000 platform is performed to identify and determine the relative frequency of each 
barcode in the tumor population.  
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The extraction of DNA from leukemic cells is performed by phenol-chloroform extraction 
according to the Cellecta Inc manual. Cells are resuspended at a concentration of 15 x 106 
/mL in Resuspension Buffer (Macherey-Nagel), containing RNase A (400µg/mL) and 10% 
SDS and incubated for 5 min at RT. One volume of phenol:chloroform:isoamyl 
alcohol 25:24:1 (Sigma-Aldrich) is added, the mix is vigorously vortexed  and 
centrifuged at 3250 x g for 90 minutes at RT. After centrifugation, the upper phase is 
collected and cleaned up from phenol residues with 1 volume of chloroform 
(VWR), vortexing and centrifuging at 3250 x g for 30 minutes at RT. The DNA is 
precipitated from the upper phase, adding 1 volume of isopropanol and 0.125 volumes of 3 
M sodium.  The mix is shacked vigorously and spinned down for 90 minutes a 3250 x g at 
RT. The pellet is washed with 70% ethanol by centrifugation at 3250 x g for 15 minutes at 
RT. The dried pellet is resuspended in sterile water and the concentration measured with 
the NanoDrop ND-1000 (Thermo). 
 
3.14 Amplification of the barcodes from the genomic DNA  
According to Cellecta Inc. suggestions, the library of barcodes from each sample is 
amplified starting from all the genomic DNA extracted from the leukemic blasts, because 
an adequate amount of DNA needs to be amplified in order to ensure full representation of 
the library of barcodes from all the cells isolated from each experimental sample. The 
lentiviral vectors of the libraries and the PCR primer are designed in order to include 
sequences complementary to the sequences of the immobilized primers necessary for 
generating amplification clusters in the Illumina’s HiSeq 2000 flow cell. The amplification 
protocol consists of two round of PCR using a nested PCR strategy (Figure 10). 
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Figure 10. Cassette of the barcodes contained in the vectors of the library. The library 
is amplified using a nested PCR strategy  that consists of two rounds of PCR. In the first 
round, primer FwdHTS3 and R2 are used to produce fragment of 275 bp. In the second 
round, the Gex-Bpi and Gex2-NR2 primers are used to amplify the 267 bp fragment ready 
to be sequenced on the Illumina platform. 
 
The goal of the first PCR is to amplify barcodes from the genomic DNA while the goal of 
the second PCR, which uses only a sampling from the 1st PCR with nested primers, is to 
separate the amplified barcodes from non-specific PCR products and the excess of 
genomic DNA. All amplification are catalysed by the Titanium Taq DNA polymerase, 
very efficient in amplifications from very high amount of DNA (Clontech-Takara).  
In detail, the PCR mix consists of: genomic DNA, 1X Titanium Taq Buffer, 0.5 U  
Titanium Taq polymerase, 400 µM of each dNTPs, 300 nM of each primer, H2O up to 100 
µl,  with 25µg of genomic DNA per PCR sample. The PCR program is the following:   
 
After the first round of PCR, for each sample all the independent PCR reactions are 
combined together in one aliquot and extensively mixed. 2µl of this mix are then used to 
perform the second round nested-PCR. The primers used for this second amplification, 
contain already the P5 and P7 adapter sequences for the Illumina’s flow cell. The reaction 
mix is: 2µl of 1st PCR, 1X Titanium Taq Buffer, 0.5 U Titanium Taq Polymerase, 400 µM 
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each dNTPs, 500 nM each primer, H2O up to 100 µl.  
The PCR program is the following:   
 
The specific primers for amplification of the library for clonal tracking and of the library 
for shRNA screening are listed in Table 5.  10 µl of the PCR products are analyzed by gel-
electrophoresis in 1X TAE on a 3.5% agarose gel in order to confirm the correct size of the 
amplicons (267 bp both for Clonal Tracking and 259 for shRNA screening) and equal 
yields of the amplified barcodes for all samples. When necessary, in order to obtain the 
same yields among all amplified samples, the number of cycles are adjusted up to a 
maximum of 24 cycles.  The correct size PCR products are purified using QIAquick Gel 
Extraction (QIAGEN) commercial kit. The quantification of the amplicons is determined 
by Qubit Assay (Invitrogen). 
Since the lentiviral shRNA library and PCR primer were designed to obtain sequences 
complementary to the sequences of the immobilized primers P5 and P7 necessary for 
generating amplification clusters in Illumina’s HiSeq 2000, the amplicons were ready to be 
sequenced through GexSeq primer.  
Table 5. Primer used for amplification of the barcodes library from the leukemic 
blasts. As already described, the P5 and P7 sequences (blue and red, respectively) are 
contained in the 2nd round primers. 
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3.15 Cloning of shRNAs in pInducer11 inducible vector 
For validation of the target genes identified by our shRNA screening, we cloned the 
corresponding shRNAs in the pInducer11 vector. For each shRNA two different copies of 
complementary oligonucleotides (a top and bottom strand) were ordered from SIGMA 
Aldrich. The sequences were the same of the shRNAs present in the library from Cellecta. 
All the forward sequences, top strand, had the same basic design, starting from 5’: XhoI 
restriction site (TCGAG), a conserved sequence (ACCGG), 21 nucleotides (specific for 
each shRNA) target sense sequence with mismatches, hairpin loop 
(GTTAATATTCATAGC), 21 nucleotides target antisense sequence (specific for each 
shRNA), terminator sequence of 4 thymines and a G to complete EcoRI restriction site. 
These sequences allow the unilateral cloning through the complementarity of restriction 
site. The complete sequences, both for the forward and reverse strands, are listed in Table 
6.  
The forward and reverse complementary oligonucleotides were mixed in a 1:1 ratio at 
2µM each. The annealing reaction was performed in 50 µl of Annealing buffer 1X (100 
mM CH3COOK, 30 mM HEPES-KOH, 2 mM Mg-acetate), incubating at 95°C for 4 
minutes, 72°C for 10 min, and at room temperature (RT) over night (O/N). The annealed 
oligonucleotides were stored at -20°C until use.   
The annealed oligonucleotides were phosphorylated in order to increase the cloning 
efficiency. The reaction was performed incubating at 37°C for 30 min in a 50 µl volume 
with 5 µl of 10x T4 DNA ligase buffer (that contains 1 mM ATP), 1 µl (10 units) of T4 
Polynucleotide Kinase (T4 PNK) (Neb) and 25 µl (1 µM) of annealing reaction. The 
reaction was stopped by heat-shock inactivation at 65°C for 20 min.  
To clone the phosphorylated oligonucleotides, the pInducer11 plasmid was digested with 
XhoI (10 Units/µg) and EcoRI (10 Units/µg) for 1 hour at 37°C. The reaction was 
performed in 1x CutSmart® Buffer (Neb). After 1 hour, the digested linearized vector was 
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separated by electrophoresis on a 0.8% agarose gel and purified using the QIAquick Gel 
Extraction Kit (Qiagen), according to the manufacturer’s specifications.  
2 nM of the phosphorylated oligonucleotides and 75 ng of linearized vector were ligated 
using 1 µl (10 Units) of T4 DNA Ligase (NEB). After transformation of the ligation mix in 
TOP10 E.coli, positive clones were screened by Colony PCR.  
 
Table 6. List of the oligonucleotides cloned in the pInducer vector for validation. The 
targets were identified by our shRNA screening. In capital letters are indicated the shRNA 
sequences; in lowercase letters the sites for restriction enzyme XhoI (tcgag) and EcoRI 
(aattc). Name Oligo, name of the target gene and number of the shRNA in the Cellecta 
library; f, forward; r, reverse. 
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3.16 Transformation of DNA into competent E. coli TOP10 cells 
 
After ligation, 25ng of DNA were used to transform E. coli TOP10 competent cells. 
Briefly, E. coli TOP10 competent cells were thawed on ice for 10 minutes. 25 ng of 
plasmid DNA was added to the cells and the tubes were carefully flicked to mix cells and 
DNA. The mixtures were: 
•   placed on ice for 30 minutes.  
•   heat-shocked at exactly 42°C for 60 seconds 
•   placed on ice for 5 minutes without mixing 
•   placed at 37°C for 60 minutes after addition of 250 µl of LB. During this phase the 
cells were shacked vigorously (250 rpm). 
•   plated (50-100 µl of each transformation) onto a selection plate (50 mg/L 
ampicillin) and incubated overnight at 37°C.  
 
3.17 Colony PCR for screening of positive clones 
After transformation in E.coli TOP10, positive clones were screened by Colony PCR. 
Individual transformants were added directly to the PCR reaction and lysed during the 
initial heating step, which causes the release of the plasmid DNA from the bacteria. The 
primers for PCR reaction (Table 7) were designed to specifically amplify a band of 448 bp 
if the construct contains the shRNA insert. For this purpose, the colonies to be tested were 
picked with a sterile tip and, after replating, directly inoculated in the appropriate PCR mix 
(1X Taq Polymerase Buffer, 400 mM forward and reverse primers, 1U Taq Polimerase 
(NEB), 200 mM dNTPS) and amplified according to the following protocol: 
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Table 7. Primers for colony PCR. 
 
 
Positive clones were inoculated in an appropriate volume of LB, containing ampicillin 
(100 mg/L), and grown at 37°C, shacking vigorously (250 rpm) O/N. For DNA extraction 
NucleoBond Xtra Maxi or NucleoSpin Plasmid (noLid) (Macherey-Nagel) were used 
according to the volume of growth and the manufacturer’s instructions. The purified 
plasmid DNA was quantified using NanoDrop ND-1000 (Thermo). Quality assessmant 
was based on the ratios of absorbance 260nm/280nm and 260nm/230nm. For DNA a 
260/280 ratio of ~1.8 and 260/230 of 2.0-2.2 was generally accepted as “pure”.  
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4 RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   60 
4.1 Establishment of a bank of AMLs   
Instrumental for this study was the collection of both murine and human leukemic samples, 
available for our experiments without limits of accessibility. For this reason we firts 
established a bank of leukemic samples. In particular, since human acute myeloid leukemia 
(hAML) xenotransplanted in immunocompromised animals retain phenotypic 
characteristics of the original sample, we established xenografts of blasts collected from 
patients affected by AMLs. As host, we used immunodeficient mice with components of 
the human immune system, the NOD SCID IL2RG null (NSG) immunocompromised 
mice. NSG mice have been shown to support greater engraftment rates of human 
hematopoietic stem cells (hCD34+ cells) than all other strains75. Our protocol, as described 
in details in the Materials and Methods, consists of the intravenous injection of CD3-
depleted mononuclear bone marrow (BM) or peripheral blood cells freshly collected from 
AML patients in 6-8 weeks old NSG mice. The development of the disease is monitored 
by the level of engrafment of the human blasts in the peripheral blood (PB) of the 
transplanted animals by FACS analysis, after staininig of the PB cells with antibody 
specific for the human CD45 hematopoietic surface antigen (hCD45). Up to date, we 
transplanted AML blasts collected from 77 patients and obtained successful engrafment of 
33, of which 16 could be serially passaged in secondary recipients in order to expand, 
collect and store cells for subsequent experiments. All the successfully engrafted 
leukemias have been characterized for their immunophenotype and main cytogenetic 
alterations. Moreover, the samples have been sequenced by Sanger for detection of 
mutations in NPM1 and FLT3, the most frequently mutated genes in AMLs. In our lab we 
have now established a bank of xenotransplanted hAMLs representative of leukemias with 
diverse clinical features belonging to different risk stratiﬁcation groups.  
The samples that we were able to infect in our study and their main genetic characteristics 
are reported in Table 8.  
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Table 8. Xenotransplanted human AMLs used in our study: leukemic samples were 
characterized for the principal recurrent mutations, NPM1c+ and FLT3-ITD, and for their 
karyotype. WT: Wild-type; MUT: mutated.  
 
 
 
For the murine AMLs, we collected several samples from transgenic animal models 
characterized by the expression of the fusion protein PML-RAR (mAPL), the mutant 
NMP1 (NMPc+) and the combination of NPMc+ with Flt3-ITD (NMP/Flt3). We started 
our experiments on the APL model, that will be presented in this thesis.  
The mCG-PML-RARalfa knock in (KI) mice43 express the PML-RAR fusion protein under 
the control of the catepsin-G promoter. These animals develop spontaneous leukemias with 
a frequency of ~55% and an average latency of 11 months. The developed leukemias are 
clinically and phenotypically undistinguishable from the promyelocytic leukemias 
developed in human patients that harbor the translocation t(15;17). We collected blasts 
from the spleen and bone marrow of PML-RAR KI mice at signs of disease, expanded 
them in secondary recipients and froze the cells in several aliquots for our experiments.  
4.2 Experimental approach 
Our experimental approach has a common workflow for both the clonal tracking analysis 
and the in vivo screenings of shRNA libraries (Figure 11).  It is based on the infection of 
freshly-isolated leukemic blasts with lentiviral libraries and their transplantation in 
recipient animals. We infect blasts at low multiplicity of infection (MOI), to ensure single 
retroviral integration per cell. After infection, we divide the leukemic blasts in two pools. 
From the first pool we extract genomic DNA to be used as the reference starting point, 
after infection in vitro. The second pool is transplanted in recipient animals. At the onset of 
leukemia in the transplanted animals, usually when the engraftment reaches about the 90%, 
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we collect leukemic blasts and extract genomic DNA.  From genomic DNA of the two 
pools we prepare libraries of barcodes by PCR amplification and submitt to high 
throughput sequencing by Illumina. Bioinformatic analysis of the barcodes allows 
comparison of library composition before and after tumor growth in vivo (Figure 11). 
These analyses allow us to identify and track the fate of the different LICs for the clonal 
tracking experiments and to identify biologically relevant genes in the shRNA screening, 
as described in more details in the following sections. 
 
Figure 11. Workflow of our experimental approach. Freshly isolated leukemic cells, 
derived from mouse models or from xenotransplanted human samples, are infected at low 
MOI with our lentiviral libraries. After infection, half of the sample is used as a reference 
of infection in vitro and the remaining half is transplanted into recipient mice. After 
development of the leukemia in vivo, the recipients are sacrificed and the main organs and 
tissues (spleen and bone marrow) infiltrated by the leukemic cells are collected. From both 
samples, we extract the genomic DNA and the libraries of barcodes are prepared by PCR 
amplification and sent to sequencing by Illumina. Analysis of the barcodes is performed 
using bioinformatics pipelines in order to compare the composition of barcodes in the two 
libraries, right post-infection and following leukemia onset.In the clonal tracking 
experiments, after development of the leukemia in the primary recipient, part of the 
collected blasts are serially transplanted in secondary and tertiary recipients in order to 
follow the evolution of the disease. 
 
We first defined appropriate experimental conditions for our in vivo studies: infectability 
of the primary leukemic blasts with the lentiviral vectors of our libraries and their 
transplantability in recipient animals. We tested different protocols of infection and found 
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that spinoculation at 2300 rpm for 90 min at RT as the most efficient. Moreover, since 
primary leukemic blasts tend to lose viability in culture, we infected the blasts immediately 
after isolation from transplanted leukemic mice. Even using the same protocols and MOI, 
we observed that the efficiency of infection, measured as percentage of TagRFP-positive 
(RFP+) cells by FACS analysis, is very variable among samples and some leukemias failed 
to be infected. However, once infected, the leukemic blasts, after transplantation in 
recipient animals, are able to engraft and tend to maintain the same percentage of RFP+ 
cells following leukemia development in vivo (Figure 13), suggesting that the lentiviral 
infection does not affect homing and growth properties of LICs. Notably, the infected 
blasts are not counterselected during in vivo leukemogenesis. 
A critical aspect of both clonal tracking and shRNA screenings, is the presence of single 
integrants and, as a consequence, single barcodes per cell. In the clonal tracking, in fact, in 
order to be able to track single cells independently, each infected cell must be identified by 
a unique barcode. In the shRNA screening, instead, we need a single integrant because we 
need to ensure that the observed phenotype is supported by knock down of a single gene 
per blast. To this aim, we evaluated the number of integrants per cell by qPCR according 
to the protocol described in Material and Methods. We determined that an efficacy of 
infection of around 20% assures a single integrant per cell. Because, in our experimental 
conditions, an efficiency of infection <20% is usually obtained with a MOI of 2, we infect 
the leukemic blasts with this MOI. As reported in section 4.4.1 this MOI guarantees us to 
have one integration per cell.  
 
4.3 Clonal tracking experiments 
 
The rationale of our clonal tracking experiments is to mark each leukemic cell with a 
specific genetic marker, the barcode, that can be stably transmitted to its progeny and 
tracked in a complex cellular population to establish their contribution to leukemia 
development in vivo. Thus, in our clonal tracking analyses we considered two parameters: 
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the identity of the barcode, that identify each leukemic clone, and the frequency of each 
barcode in the leukemic population, as indirect measurement of the contribution of each 
clone to leukemia development. In more details, for each sample, the sequences (reads) 
derived from the Illumina platform are aligned to the reference library provided by the 
manufacturer (Cellecta Inc.), without allowing mismatches. For each barcode identified, 
we calculate the relative frequency in the tumor sample, as the ratio between the reads that 
identify that specific barcode and the total number of reads obtained from the sequencing 
of the library for each sample.   
 
4.3.1 Infection of AML blasts with the clonal tracking library 
To track clones originated by individual leukemic cells inside the tumor population, we 
infect leukemic blasts with a lentiviral library containing 30 million different barcodes. 
The complexity of the library is generated by 30 million different combinations of two 
barcodes of 18 degenerated nucleotides each. This very high complexity allows to mark 
each cell with a unique barcode. Indeed, infecting a low number of cells (1 million) with a 
library that contains a very high number of different barcodes minimize the probability of 
obtaining integration of the same barcode in two different cells. In particular, for our 
studies we infected human blasts of one xenotransplanted human AML, AML-IEO20, and 
murine blasts from a transgenic PML-RAR KI mouse, mAPL18. In order to perform our 
clonal tracking analysis in parallel in different animals, for both leukemias, we infected the 
blasts with the 30 million-barcodes library in 5 independent cell aliquots and transplanted 
each of them in 5 recipients animals (Figure 12). We determined by FACS analysis the 
percentage of cells expressing the reporter gene TagRFP (RFP) and obtained ~15% 
infection for AML-IEO20 and ~8% for mAPL18. For two of these recipients,  
chosen on the basis of TagRFP signal in primary mice, we serially transplanted the 
leukemic blasts up to the third passage (X3) for AML-IEO20 and up to the second passage 
(X2) for mAPL18 (Figure 12). 5x105 blasts were retransplanted in each secondary 
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recipient in serial passages. From each recipient, at the onset of leukemia, we collected the 
blasts, extracted the genomic DNA, amplified by PCR the barcodes and sequenced them 
by NGS.  
 
 
Figure 12. Scheme of the clonal tracking experiments. For each leukemia, AML-IEO20 
or mAPL18, we infected with the 30 million barcodes library 5 independent pools of blasts 
(infection). For each leukemia five pools were transplanted in independent primary 
recipient mice (X1). The blasts collected from the primary leukemias, indicated with the 
arrows, were transplanted in several secondary recipients (from 2 to 5 mice, X2) and, in 
particular for AML-IEO20, the blasts collected from the secondary leukemias, were 
transplanted in tertiary recipients (X3). Each recipient mouse is identified by an ID number 
(ID). 
 
For AML-IEO20, following leukemia development in vivo, all transplanted animals 
maintained, in all the hematopoietic compartments analysed (peripheral blood, spleen and 
bone marrow), a percentage of RFP+ cells similar to the one observed following infection 
in vitro (Figure 13A and 13B). However, while following the primary transplantation the 
percentage of RFP+ cells was very similar in all 5 recipient animals (Figure 13A and 13B), 
in the secondary recipients the percentage of RFP expression differed in recipients of 
leukemic blasts deriving from different primary donors (Figure 13C). Nonetheless, the 
RFP signal was very consistent for all the recipients of the same donor (Figure 13C).  
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Taken together, these results indicate that the infected blasts are not counterselected in vivo 
and the leukemogenic potential of LICs is not affected by infection with the clonal tracking 
library. 
 
Figure 13. Efficacy of infection of AML-IEO20 and engrafment of the infected blasts 
following transplantation in vivo.  A) Leukemic blasts from AML-IEO20 were infected 
with the 30 million barcodes library in 5 sets of 1 million cells each. After infection, half of 
the 5 sets of cells were transplanted independently in 5 recipient mice. At the onset of 
leukemia, the leukemic blasts were collected from different hematopoietic compartments: 
peripheral blood (Blood), spleen (Spleen) and bone marrow (BM). The level of RFP signal 
(% TagRFP positive cells) was evaluated by FACS in each compartment for each 
recipient. Each symbol represents a recipient animal. B) Panel B shows the level of RFP 
signal in the 3 leukemic compartments analysed for each recipient animal (Mouse). C) 
Level of engrafment of AML-IEO20 in secondary recipients. At the onset of leukemia, the 
leukemic cells were collected from spleen (Spleen) or bone marrow (BM) of each primary 
recipient (Mouse) and were retransplanted in 3 or 4 secondary recipients. As described for 
the primary leukemias, the RFP signal was evaluated in the peripheral blood of every 
secondary recipient at the onset of the tumors. Labels are as for panel A. 
 
 
From all pools of leukemic cells collected after development of the leukemia in vivo the 
barcodes libraries were amplified by PCR from the genomic DNA of the collected blasts.  
As an example, Figure 14 shows the amplified library for the primary tumors. For each 
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tumor, after PCR amplification, we obtained a specific band corresponding to the expected 
size of 267 bps of the barcodes.  
 
Figure 14. Amplification of the libraries of barcodes from AML-IEO20. The libraries 
were prepared by PCR amplification from the genomic DNA extracted from blasts of 
AML-IEO20 infected with the 30 million barcodes.  Inf, blasts after infection in vitro. BM 
(bone marrow) and SPL (spleen) from animals transplanted with the infected primary 
leukemias. The PCR products were analysed on a 3.5% agarose gel and appeared to be 
specific and of the expected size (267 bps). MW, 100 bp Marker; pRSI, purified vector 
used as positive control; Neg Ctrl, Genomic DNA used as negative controls. 
 
In contrast to what we observed for the human AML, for the murine mAPL18 leukemia, at 
the onset of the disease after transplantation, all the primary recipients showed a very low 
percentage (~1%) of RFP+ cells (Figure 15A). This level of RFP+ cells was consistent in 
all hematopoietic compartments analyzed (Figure 15A and 15B). Loss of RFP expression 
can be explained by two hypothesis: i) the RFP+ positive cells were counterselected in vivo 
in the mAPL18; ii) PML-RAR downregulates the expression of the reporter gene by gene 
silencing, as it has been previously reported97. In order to test the first hypothesis and 
determine if the infected blasts are indeed ablated by the leukemic population during in 
vivo growth, we tested by PCR amplification if the lentiviral integrations were still 
detectable in the leukemic blasts collected from the primary recipients animals. We 
performed a PCR on the genomic DNA of these blasts using primers specific for the 
lentiviral sequences GAG and WPRE. As shown in Figure 15C, with both copies of 
primers, in 4 out of the 5 transplanted animals we amplified specific bands, corresponding 
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to the viral integrations. These data suggest that the infected cells are not counterselected 
and more likely there is silencing of the reporter gene. 
 
 
Figure 15. Efficacy of infection of mAPL18 and engrafment of the infected blasts 
following transplantation in vivo. Leukemic blasts from mAPL18 were infected with the 
30 million-barcodes library in 5 sets of 1 million cells each. After infection, half of the 5 
sets of cells were transplanted independently in 5 recipient mice. At the onset of leukemia, 
the leukemic blasts were collected from different hematopoietic compartments: peripheral 
blood (blood), spleen (spleen) and bone marrow (BM). Panel A shows the RFP signal in all 
compartments analyzed at the onset of leukemia compared to the signal detected in the 
blasts right after infection and prior to transplantation (Infection). For each compartment, 
each symbol represents a recipient animal. B) The RFP signal (% TagRFP positive cells) 
was evaluated in each compartment for each recipient (Mouse) when leukemic engrafment 
in the PB reached ~90%. C) Because we observed loss of RFP signal following leukemia 
onset, we extracted the genomic DNA from the blasts and determined by PCR 
amplification if the viral integrations were still detectable. We used two sets of primers 
specific for lentiviral sequences: GAG and WPRE. Specific bands were detectable in 4 out 
of 5 transplanted animals. As positive controls we used: two lentiviral vectors carrying 
GAG and WPRE sequences (pRSI and pLKO.3g vectors) and murine genomic DNA from 
a murine leukemia infected at high MOI (pRSI infected cells). As negative controls we 
used: genomic DNA from not infected cells (Genomic DNA) and no DNA (H2O).  
 
 
Indeed, in our laboratory, it as been previously observed that in this same leukemic model, 
administration of retinoic acid (RA) in vivo induces the rescue of the signal of the reporter 
gene GFP, introduced in the leukemic blasts by lentiviral infection. In that particular 
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experiment, we infected the blasts of mAPL18 with a lentiviral vector encoding for a 
fusion gene between histone H2B and GFP (H2B-GFP). We obtained an efficacy of 
infection of ~40% (Figure 16). However, at the onset of the leukemia, we could no detect 
any H2B-GFP+ blast in the peripheral blood of any of the recipient mice. Suspecting a 
silencing of the reporter due to the presence of PML-RAR (Figures 15A and 16). We, 
therefore, treated the leukemic mice with RA (40mg/Kg every other day for 5 
administrations). As shown in Figure 16, after RA administration, we observed 
reexpression of the H2B-GFP in up to ~60% of the circulating blasts, confirming our 
hypothesis that PML-RAR induced silencing of reporter gene.  
 
 
Figure 16. Retinoic acid treatment induces reexpression of the H2B-GFP fusion 
protein in the mAPL18 blasts. The percentage of blasts expressing the H2B-GFP (% of 
GFP) was evaluated by FACS analysis in the leukemic blasts: i) after infection in vitro 
(efficacy of infection); ii) at the onset of the leukemia in one representative transplanted 
recipient (onset); iii) in the transplanted recipients (Mouse 1, Mouse 2 and Mouse 3) after 
treatment with 40 mg/kg of reinoic acid (RA treated). Ctrl, negative control: not 
transplanted mouse. 
 
We are currently trying to address this issue in the blasts infected with the clonal tracking 
library. We already transplanted new recipient mice with the blasts derived from one of 
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these mAPL18 samples and we plan to treat them with pharmacological doses of retinoic 
acid in order to see if we are able to resume RFP expression.  
Considering that the infected cells were still detectable in the leukemic samples, we 
decided to proceed with the amplification of the library of barcodes from the genomic 
DNA extracted from all pools of leukemic cells. In order to established a threshold for 
clonal identification, before amplification by PCR of the library of barcodes, we added a 
spike-in control to the genomic DNA of each sample. As spike-in control, we used 
genomic DNA extracted from NB4 cells infected with specific barcodes (described in 
detail in the following paragraph 4.3.2). Figure 17 shows an example of the PCR 
amplification for the libraries from the primary tumors of mAPL18. For each tumor, we 
obtained two specific bands: one corresponding to the expected size of 267 bps for the 
barcodes of clonal tracking library and one of 249 bps for the spike-in control barcodes 
(Figure 17). 
 
 
Figure 17. Amplification of the libraries of barcodes from mAPL18. The libraries were 
prepared by PCR amplification from the genomic DNA extracted from blasts of mAPL18 
infected with the 30 million barcodes. The PCR products were analysed on a 3.5% agarose 
gel and appeared to be specific and of the expected size (267 bps for the barcodes of clonal 
tracking library and one of 249 bps for the spike-in control barcodes). Vitro M2 and M3, 
blasts after infection in vitro. MW, 100 bp Marker; Positive Ctrl, purified vectors used as 
positive control; Negative Ctrl, Genomic DNA of not infected cells used as negative 
control. 
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For both the human and the murine leukemia, for all samples with successful 
amplification, after gel purification, the barcode-libraries were sequenced with the Illumina 
HiSeq platform. 
 
4.3.2 Establishment of a threshold for clone identification 
One major issue in this type of experiments is the establishement of a proper threshold for 
the identification of the sequence tags to be tracked during the clonal analysis. In order to 
perform internal calibration and correct for technical issues related to genomic DNA 
extraction and to amplification by PCR, we added an internal control to each experimental 
sample of the murine leukemia, during the phase of genomic DNA extraction and 
preparation of the libraries for sequencing. These ‘‘spiked-in’’ controls consisted of 
defined numbers of clonal NB4 cells (10, 100, 1,000, 10,000 and 50,000 cells) infected 
with lentiviral constructs each harboring a known single barcode of 18 nucleotides, that 
can be amplified with the same set of primers used for the clonal tracking library. To 
ensure that each cell contained a single integrant, NB4 cells were infected at low MOI (5-
10% infected cells). To obtain a pure population for each spiked-in barcode, we selected 
clones with puromycin. The correct number of cells was obtained by serial dilution and 
added to the leukemic blasts population before extraction of the genomic DNA.  
After sequencing and perfect macht alignment to the known spike-in barcodes, for each 
experimental dataset, we performed a regression analysis to establish the relationship 
between the number of reads obtained from the sequencing of each spiked-in barcode and 
the number of cells from which the spiked-in sequences had been obtained (Figure 18 and 
Table 9). 
 
 
 
 
   72 
 
Figure 18. Regression line in spike in experiments. The relationship between the 
absolute number of cells and the number of reads obtained by HTS for each spike-in 
control is linear. This relationship was measured for each experimental sample of clonal 
tracking performed on murine leukemias. The solid lines indicate the linear regression that 
fits the data for each experiment (each colour identifies a different sample). Values are 
expressed in logarithmic scale (Log10). A. Linear regression obtained considering all 
dilutions of the spike-in control cells. B. Linear regression obtained eliminating the spike-
in control equivalent to 10 cells, which, for some of the sample, clearly appears to be out 
of the linear range. 
 
As shown in Figure 18, for each experiment we observed a linear relationship between the 
numbers of reads obtained from the sequencing of each spiked-in barcode and the numbers 
of cells added as spike-in control to the genomic DNA. Even if we were able to identify 
also the barcodes corresponding to 10 cells in 7 out of 8 samples analysed, for 4 samples 
this data point was clearly out of the determined linear range (Figure 18A and Table 9). 
These data suggests, within our experimental conditions, a lower limit of detection of 
barcodes at around >10 cells. Indeed, considering only the spike-in controls from 100 to 
50,000 cells we observed a perfect linear correlation with R2 grater than 0.99 between 
number of reads and number of cells (Figure 18B and Table 9), indicating that the number 
of reads is directly proportional to the number of infected cells harbouring a specific 
barcode in the tumor population. Moreover, this linear relationship is maintained also for 
barcodes identified by a very high number of reads (up to ~7 millions), suggesting that our 
protocol for amplification of the library does not affect the relative frequency of each 
barcode within the population. 
   73 
After this analysis, we decided to set the threshold for identification of the clones within 
the tumor population to a minimum of 10 cells. Therefore, based on the linear regression of 
the spike-in, for each sample, we calculated the number of reads that correspond to 10 cells 
and used this number to set the threshold of the background and determine the clonal 
composition of each murine tumor (Table 9).  
 
Table 9. Number of reads obtained by sequencing (obtained after HTS) or calculated 
by regression analysis (Calculated) for the spike-in barcodes. For each number of cells 
for the spike-in controls is reported the number of reads obtained by HTS. Considering 
that, for at least 4 out of the 8 experiments reported, the spike-in barcode equivalent to 10 
cells has a number of reads clearly out of the linear range, we determined the expected 
number (Calculated) of reads for 1 and 10 cells, considering the linear regression 
parameters after removal of the 10-cells data points (see panel B of Figure 18). R2 is the 
correlation coefficient that measures the reliability of the linear relationship between our 
two variables. R2 tot, coefficients obtained considering all data points (panel A of Figure 
18). R2 adj, coefficients of the linear regressions after removal of the 10-cells data points 
(panel B of Figure 18). 
	  
 
 
As described in the previous paragraph, for the first passage (X1) of mAPL18, we analysed 
the spleen cells from two independent recipient mice, Mouse 2 and Mouse 3. After HTS 
and perfect-match alignment, we obtained 1.89x107 and 1.42x107 total reads, respectively, 
accounting for 290 different barcodes for Mouse 2 and 226 for Mouse 3 (Table 10). 
Applying the threshold determined through the spike-in controls, for each sample, we 
considered as “real” traceable clones only the clones identified by barcodes with a number 
of reads ≥ than the number of reads calculated by linear regression to correspond to 10 
cells: 437 and 1,549 reads for Mouse 2 and Mouse 3, respectively (Table 10). Applying 
this threshold we obtained 40 and 21 different clones for the two X1 samples. The relative 
frequency of these clones ranges from 0.002% to 49.20% for Mouse2 and from 0.012% to 
1 10 10 100 1000 10000 50000 R2 tot R2 adj
X1_M3 214 1,549 370 14,892 55,648 445,289 3,095,749 0.87082 0.9921
X1_M2 45 437 0 4,017 45,016 387,987 1,925,170 0.97309 0.99169
X2_M2_ID1 170 1,585 2 17,100 113,476 1,233,100 6,633,311 0.85605 0.996
X2_M2_ID2 174 1,622 871 18,488 101,221 1,361,270 6,830,331 0.98919 0.99139
X2_M2_ID3 141 1,318 6,252 12,497 114,384 949,392 5,358,466 0.97942 0.99697
X2_M2_ID4 380 2,884 1,004 27,494 120,795 1,167,220 6,292,147 0.98223 0.99397
X2_M3_ID1 218 1,557 24 3,378 11,426 122,388 681,267 0.94168 0.98671
X2_M3_ID2 151 1,083 17 22,989 81,168 907,633 4,717,180 0.88229 0.98707
Number of Reads/Barcodes
Sample
Calculated Obtained after HTS
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42.05% for Mouse3. However, the total number of clones above the threshold covers more 
than 99.9% of sequenced reads. 
Applying the same threshold described for the X1 passage to each X2 sample, again, we 
always obtained a number of clones (from 11 to 26) that covers more than 99% of the 
reads (Table 10).  
 
Table 10. Clonal composition of the leukemia mAPL18. For each passage (X) of 
leukemia transplantation are described: the total number of reads obtained by sequencing, 
the total number of barcodes identified, the number of barcodes present in more than 10 
cells, the percentage of sample analysed and the frequency (%) of the less represented and 
of the most represented clone. It is worth underlying that, for each leukemia, more than 
99% of the sample was analysed. SPL, spleen; ID, mice from which the tumor cells are 
derived for transplantation as described in Figure 12. 
	  
 
 
For the experiments of clonal tracking in the AML-IEO20, the spike-in internal control 
was not available, therefore, in order to establish a threshold for clone identification, we 
decided to take advantage of the data obtained for the spike-in controls of the murine 
experiments. We observed that, for the murine leukemia, independently from the total 
number of reads obtained and from the number of reads used to establish our threshold, the 
frequencies of the less represented clones in the tumors were always very similar in the 
majoriy of the samples with a mean average of 0.04% (excluding the highest (0.164%) and 
the lowest (0.002%) values) (Table 10, % lowest clones). Based on our definition of 
threshold for the murine leukemia, we can extrapolate that the frequency of 0.04% 
corresponds to the frequency of the clones represented by 10 cells in the tumor. We used 
these parameters to establish a threshold also in the human samples. Therefore, in order to 
Passage Cells transplanted
Sample 
Analysed
Organ 
Analysed
Total 
Reads 
(x106)
Total 
Barcodes
Barcode 
Founded 
≥10 cell 
% of 
samples 
analysed
% lowest 
clone
% highst 
clone
ID2 SPL 14.2 226 21 99.91 0.012 42.056
ID3 SPL 18.9 290 40 99.98 0.002 49.214
ID2.1 SPL 33.5 338 26 99.71 0.061 76.371
ID2.2 SPL 30.9 157 19 99.75 0.062 76.508
ID2.3 SPL 32.01 164 21 99.86 0.046 78.918
ID2.4 SPL 28.6 167 11 99.42 0.164 78.16
ID3.1 SPL 4.14 124 13 99.78 0.041 82.124
ID3.2 SPL 4.72 244 20 99.87 0.039 78.16
X1 Infected cells
X2
Spleen             
(from X1 ID2)
Spleen             
(from X1 ID2)
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study clonal evolution in vivo, for each passage of hAML-IEO20, we considered and 
compared exclusively the barcodes with a frequency ≥0.04%. 
As for the murine leukemia, we observed that, in each sample analysed, the majority of the 
clones were present with a very low frequency and that only few tens were above the 
threshold of 0.04%. However, for all samples analysed for AML-IEO20, it is clear that all 
clones with a clonal frequency ≥0.04% cover more than 99% of sequenced reads. Table 11 
shows the results for the clonal analysis of serial transplantation of the leukemia derived 
from Mouse 2 and Table 12 for the leukemia derived from Mouse 4.  
 
Table 11. Clonal composition of the AML-IEO20, Mouse ID2. For each step (X) and 
each organ analyzed are described: the total number of reads obtained by HTS, the total 
number of the barcodes identified, the number of barcodes with a frequency ≥0.04%, the 
percentage of tumor sample analysed and finally the percentage of the most represented 
clone. Considering only clones with a frequency ≥0.04%, more than 99% of the tumor is 
always analyzed. BM, bone marrow; SPL, spleen; ID, mice from which the tumor cells are 
derived for transplantation as described in Figure 12. 
	  
 
 
 
 
 
 
 
Passage Transplanted cells
Sample 
Analysed
Organ 
Analysed
Total Reads 
(x106)
Total 
Barcodes
Barcodes 
with 
freq≥0,04%
% of samples 
analysed
% highest 
clone
BM 107 3413 66 99.30 18.75
SPL 94.6 5236 87 99.02 16.54
BM 66.4 329 27 99.88 34.21
SPL 28.5 317 32 99.85 29.8
BM 44.8 318 16 99.76 61.44
SPL 41.8 424 22 99.87 71.85
BM 85.1 430 15 99.76 43.37
SPL 98.0 532 25 99.87 46.56
BM 54.2 227 23 99.82 43.67
SPL 35.2 199 21 99.84 40.34
Spleen        
(from X2 ID1) ID3.1 SPL 1.76 84 8 99.94 72.23
Bone marrow 
(from X2 ID1) ID3.2 SPL 1.30 81 4 99.81 52.32
Spleen           
(from X2 ID4) D3.3 SPL 7.12 69 9 99.86 44.72
Bone marrow          
(from X2 ID4) ID3.4 SPL 2.97 78 4 99.60 41.53
X3
X1 Infected cells ID2
 X2
Spleen               
(from X1 ID2)
ID2.1
ID2.2
Bone marrow 
(from X1 ID2)
ID2.3
ID2.4
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Table 12. Clonal composition of the AML - IEO20, Mouse ID4. As for Mouse 2, for 
each animal transplanted with AML-IEO20 are described: the total number of reads 
obtained by HTS, the total number of barcodes identified, the number of barcodes with a 
frequency ≥0.04, the percentage of tumor sample analysed and, finally, the percentage of 
the most represented clone. As for Mouse 2, applying a threshold of clonal frequency 
≥0,04% more than 99 % of the tumor is analyzed in most of the samples. BM, bone 
marrow; SPL, spleen; ID, mice from which the tumor cells are derived for transplantation 
as described in Figure 12. 
	  
 
 
4.3.3 The clones defined by the clonal tracking experiments identify leukemia 
initiating cells (LICs) 
Up to date, the gold standard to measure the frequency of LICs, and of HSCs in general, is 
the limiting dilution transplantation (LDT) assay. In this assay, a serial dilution of cell 
doses of the leukemia are transplanted in several recipient mice. The frequency of LICs is 
then estimated based on the ratio between the total number of mice transplanted for each 
cell dose and the number of mice positive for reconstitution at each cell dose, using the 
web tool Extreme Limiting Dilution Analysis (ELDA)98.  This software calculates a range 
of stem cells frequency within the tested cellular population, with a confidence interval of 
95%. Thus, we calculated LIC frequencies of the leukemias used for clonal tracking 
experiments, using the LDT assay. As listed in Table 13, the stem cell frequency 
determined by ELDA is 1/989 (confidence interval: lower 1/1844; upper 1/530) and 1/471 
(confidence interval: lower 1/838; upper 1/265) for AML-IEO20 and mAPL18, 
respectively. 
 
 
Passage Transplanted Cells
Sample 
Analysed
Organ 
Analysed
Total Reads 
(x106)
Total 
Barcodes
Barcodes 
with 
freq≥0,04%
% of 
samples 
analysed
% highest 
clone
X1 Infected cells ID4 BM 41.7 1539 96 98.98 16.82
ID2.1 SPL 49.2 157 17 99.89 29.17
ID2.2 SPL 12.5 171 13 99.94 34.26
ID 2.3 SPL 20.2 60 5 96.72 31.42
ID2.4 SPL 33.8 113 11 99.9 24.68
ID2.5 BM 83.9 595 22 99.47 31.14
ID3.1 BM 1.96 65 8 99.62 47.99
ID3.2 BM 3.03 54 8 99.9 49.33
X2 Bone marrow                   (from X1 ID4)
X3 Bone marrow            (from X2 ID4)
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Table 13. Estimation of LIC frequency by LDT assays. Experiments of limiting dilution 
transplantation were performed both for AML-IEO20 and mAPL18. The frequency of 
stem cells was calculated using the software ELDA, based on the number of animals that 
developed leukemias out of the total number of transplanted animals for each cell dose. 
 
 
The experimental conditions of the LDT assay are quite different from the experimental 
conditions used in our studies, in which we transplant the leukemic population in bulk. We 
decided to compare the two methods for LIC determination in order to assess if the 
barcoding strategies and the threshold we defined for our study are reliable in terms of 
identification of LICs. We, therefore, determined the LIC frequency for AML-IEO20 and 
mAPL18 based on the results of clonal tracking experiments. In particular, we estimated 
the LICs taking into consideration the percentage of barcoded cells in the transplanted 
leukemic population (% of infection) and the average number of clones identified in the 
passage X1 for each leukemia (barcodes above the set thresholds), applying the following 
formula: 
𝐿𝐼𝐶	  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 1: #𝑜𝑓	  𝑇𝑟𝑎𝑛𝑠𝑝𝑙𝑎𝑛𝑡𝑒𝑑	  𝑐𝑒𝑙𝑙𝑠: 𝐵𝑎𝑟𝑐𝑜𝑑𝑒𝑠	   > 10	  𝑐𝑒𝑙𝑙𝑠 ∗ 100%	  𝑜𝑓	  𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛  
 
For human AML-IEO20, for all three primary samples analysed, the LIC frequency 
calculated based on the results of the clonal tracking experiments are within the confidence 
# of cells per 
mouse
# of mice 
transplanted
# of dead 
mice
# of cells per 
mouse
# of mice 
transplanted
# of dead 
mice
500,000 3 3 1,000,000 5 5
100,000 5 5 200,000 9 9
50,000 4 4 100,000 10 10
10,000 8 8 50,000 9 9
5,000 9 9 20,000 7 7
1,000 11 6 10,000 15 15
500 5 3 5,000 0 10
500 18 11
50 8 2
Lower Estimate Upper
1,844 989 530
Lower Estimate Upper
838 471 265
1/(stem cells frequency)  
murine APL #18human AML-IEO20
Confidence intervals for
1/(stem cells frequency)  
Confidence intervals for
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intervals calculated by ELDA and the average LIC frequency is 1:938, virtually identical 
to the one of 1:989 estimated by ELDA (Table 13 and 14). For the murine APL, the LIC 
frequencies calculated based on our clonal experiments were slightly below the range 
determined by LDT (1:838), with an average frequency of 1:1452 (Table 14).  
Our data show that, in spite of the different behaviours growth patterns of the different 
leukemic samples, the LDT and the clonal tracking experiments give similar results, 
indicating that the clones identified through our experimental strategy identify bona fide 
LICs.  
 
 
Table 14. Comparison of the LIC frequencies. The LIC frequency were calculated by 
ELDA or based on the number of clones identified in the passage X1 of our clonal tracking 
experiments.  
 
 
 
4.3.4 The clonal composition of the leukemic blasts in the different hematopoietic 
compartments is highly similar 
We first asked if there is a difference in the clonal composition of leukemic blasts collected 
from different hematopoietic organs, e.g. if there is selection of different clones within 
different hematopoietic compartments. To this end, we performed clonal tracking analysis 
of blasts derived from spleen and bone marrow of the human AML-IEO20 from the 
leukemia transplanted in Mouse 2. In particular, we analysed the blasts derived from 
spleen or BM of the primary recipient (X1) and from 4 independent secondary recipients 
(X2) (Figure 19). 
 
Leukemia Sample 
Analysed
Organ 
Analysed
# of clones 
in X1
LIC 
fesquency 
by ELDA
LIC fesquency 
by Clonal 
Tracking
ID2 Spleen 87 1:862
ID2 Bone marrow 64 1:1,172
ID4 Bone marrow 96 1:781
ID2 Spleen 40 1:1,000
ID3 Spleen 21 1:1,904
Human           
AML-IEO 20
Murine APL 
#18
1:989
1:471
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Figure 19. Clonal evolution of blasts derived from spleen and BM of human AML-
IEO20 (Mouse ID2) in two passages of serial transplantation. Leukemic blasts 
collected from spleen (left bars for each mouse) and bone marrow (right bars for each 
mouse) of the X1 mouse (ID2), were transplanted in 4 secondary recipients (X2). At 
leukemia development in the secondary recipients, barcodes analysis was performed from 
spleen and bone marrow of the 4 independent animals. The graphic shows the number of 
clones identified in the two organs of each mouse. Each bar of different colour identifies a 
different clone (barcode). The height of each bar indicates the frequency of each clone in 
the tumor population. The clones are ordered bottom to top with decreasing frequency. 
Each colour corresponds to a specific clone and the colour code is maintained for all bars.  
 
 As shown in Table 11 and Figure 19, the number of clones identified was very similar not 
only between spleen and BM extracted from the same animal but also between the two 
compartments from two independent recipients. 
Notably, the clonal composition within the two compartments was very similar both in 
terms of clonal identity and clonal frequency among all recipients (Figure 20). Indeed, the 
correlation of the clonal distribution between spleen and BM was very high (R=0.86) for 
the X1 passage of transplantation and increased further in the second passage of 
transplantation, with a Pearson correlation coefficient >0.95 for all X2 samples, with the 
exception of one mouse (ID2.2), which showed a different clonal composition, as 
compared to all other animals (Figure 26).  
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Figure 20. The clonal composition of the leukemic blasts in spleen and BM is highly 
similar. A) Clonal distribution of the leukemic clones in the spleen (x axis) and in the BM 
(y axis) in the X1 mouse ID2 transplanted with AML-IEO20. The scatterplot shows the 
frequency distribution of clones expressed in logarithmic scale (Log10). Each solid circle 
identifies a clone. In the middle of the plot are clones in common between the spleen and 
BM. On the x axis the unique clones for the spleen and on the y axis the clones unique for 
the BM. B) Heatmap of the R scores determined by Pearson correlation analysis. For each 
pair of samples we calculated the correlation of the distribution of the identity and 
frequency of the clones identified in the spleen (S) and BM (B) of each indicated sample 
according to the experimental scheme and data depicted in Figure 12. ID number, mice 
from which the tumor cells are derived for transplantation; X, passage of transplantation. 
 
 
Our data indicate that there is no selection of leukemic clones within the different leukemic 
organs and that there is no clonal tropism for the distribution of the disease. Based on the 
homogeneity of the clonal analysis observed from the two hematopoietic organs, also in 
order to reduce the costs of our analysis, we decided to consider (in the subsequent clonal 
tracking analyses) only one hematopoietic compartment per recipient mouse (BM or 
spleen indifferently). 
In the following clonal tracking analysis, we considered three parameters: i) the number 
and the identity of the clones among the different transplanted mice and the different 
passages of leukemia transplantation, searching for the clones in common; ii) the relative 
distribution of the frequency of the clones within the tumor population, independently from 
their identity: we call this parameter “correlation of frequency”; iii) the frequency of each 
individual clone within the tumor population: “correlation of identity”. We performed the 
analysis of these three parameters both “horizontally”, within the different animals 
transplanted with the leukemias within the same passage of transplantation, and 
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“vertically”, looking at how these parameters varied with the serial passages of 
transplantation. 
 
4.3.5 The number of clones able to engraft and their ability to expand is very similar 
at each passage for all leukemia analysed 
We first try to understand the behavior of the same AML sample after transplantation in 
different animals and at different passages, by analysing the numbers of clones that are 
able to engraft for each leukemia at each passage. As shown in Figure 21 and reported in 
Tables 10, 11 and 12, the number of clones identified for each sample is very similar at 
each passage. This indicates that there is a limited and fixed number of LIC able to engraft 
and propagate the disease. 
 
 
Figure 21. Number of clone per passage.  For each passage the total number of engrafted  
clones identified above threshold were considered.  
 
Moreover, we noticed that within each passage, independently from their molecular 
identity, the distribution of the frequency of the clones within each transplanted animal 
was highly conserved among all the different animals, for both AML-IEO20 and mAPL18 
(Figure 22).  
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Figure 22. Clonal tracking experiment: A) human AML-IEO20 ID2, B) human AML-
IEO20 ID4, C) murine APL18 ID2 and D) murine APL18 ID3. As described in Figure 19 
each colour corresponds to a specific clone and the colour code is respected for all serial 
passages.  
 
We then used the Pearson correlation coefficient (R) to measure the degree of conservation 
of “clone frequency” among all transplanted mice within each passage. The correlation of 
frequency was very high even among mice transplanted with different leukemias and in all 
three passages of serial transplantation, as shown in the heatmap of the Pearson correlation 
(Figure 23). All Pearson correlation coefficients are above 0.66 with a mean of 0.88. This 
degree of conservation was particularly high (R >0.9): i) for all primary samples, 
independently of their human or murine origin; ii) for most of the human secondary and 
tertiary recipients, even if coming from different primary donors (human ID2 vs ID4); iii) 
for all secondary recipients of the murine leukemia, for which there was perfect identity of 
the correlation of frequency among all samples (R=1.0).  
Taken all together, our data suggest that the number of LICs and their ability to expand 
within the tumor is somehow determined and finite.  
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Figure 23. Heat map of correlation of frequency distribution. The correlations were 
ccalculated taking in consideration the distribution of frequency in each sample compared 
with the other ones from same passage. 
 
 
4.3.6 The clones that mainly contribute to leukemia development are identical and 
have similar growth potential. 
Considering the high degree of conservation, of the clones within all leukemias, both in 
terms of number and frequency distribution, we investigated if the clones that grow with 
the same frequency within each tumor have also the same molecular identity. In other  
words, we searched for clones in common among the different mice transplanted with the 
same leukemia. For each passage of transplantation, we determined the percentage (%) of 
clones in common among mice transplanted with cells from the same passage of 
transplantation. We could apply this analysis only to secondary and tertiary passages of 
transplantation, because the X1 samples derive from independent infections of pools of 
blasts that, according to our experimental condition, do not share any barcode (Figure 24). 
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Figure 24. Heatmap of percentage of common clones.  A) Heatmap of percentage of 
common clone among mice from same passages. B) Each percentage of common clones is 
calculated considering both samples.  
 
 
 
As shown in Figure 24, we observed that the percentage of common clones among the 
different samples was variable, ranging from the 8 to 95%, with  ~40% (23/58) of all the 
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analysed combinations showing <55% of common clones. Interestingly, this was true also 
for those samples showing a very high correlation of frequency (Figure 23). As an 
example, the murine leukemia showed a Pearson correlation coefficient equal to 1 for 
every comparison, and less than 50% of common clones, with two samples sharing only 
8% of common clones. Likewise for the X3 passage of the human leukemias, which 
showed correlation of frequencies of ≥0.8 for each combination, and <50% of common 
clones in most samples (8/14; ~60%) (Figure 24). These data indicates that, for most of the 
samples, the clones that contribute to leukemia development vary within the same 
leukemia and among different passages. Indeed, the numbers of unique clones for all 
leukemic samples analysed at each passage of transplantation tend to be higher for both X2 
and X3 passages (Figure 25).  
 
 
Figure 25. Numbers and relative frequencies of common or unique clones. A) We 
plotted the numbers of clones (common or unique) found among several mice from the 
same passage transplanted with the same cells. Common clones tend to be lower compared 
with the unique.  B) in this panel were considered the percentage of tumor that clones 
decribed in panel A cover. 
 
However, if we consider the percentage of tumor to which the common and the unique 
clones contribute to, we observe a statistically significant inverse correlation, suggesting 
that at each passage of transplantation the common clones contribute the vast majority of 
the tumor (mean of 80.9% and 89% for the X2 and X3 passage, respectively; Figure 25B).  
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As a consequence, analyses of the distribution of frequency within the tumoral population 
exclusively for the common clones (socalled correlation of identity) revealed that the vast 
majority of the samples of both human and murine leukemias are identical, with a Pearson 
correlation coefficient >0.9 (Fig 26). The only exceptions are one sample for each human 
leukemia: ID 2.2 for Mouse 2 (R ~ -0,138) and ID2.5 for Mouse 4 (R ~ -0,75), that clearly 
show the expansion of different clones compared to the other samples (Figure 19 and 22).  
 
 
Figure 26. Heat map of correlation of identity. Pearson correlation were calculated 
among common clones founded in each passage. 
 
Our data indicate that, with the exception of rare cases, for the leukemic samples analysed, 
the vast majority of each tumor is composed of the same identical clones and that each 
clone maintains its growth potential upon transplantation. 
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4.3.7 A clonal selection exists through evolution of the leukemia in the different 
passages 
We next investigated the pattern of evolution of AMLs, comparing the clonal composition 
of each sample from the X1 to the X2 and to the X3 passage of transplantation within 
populations of samples derived from the same primary donor. We first analysed numbers 
of clones at each passage of transplantation. Figure 27 shows that the numbers of clones 
decreases at each passage of transplantation with a mean of 62±31 for X1, of 19±7 for X2 
and of 7±2 for X3 leukemias. The decrease in clonal number is statistically significant 
among all passages, clearly indicating that each passage is associated with a strong clonal 
selection.  
 
 
Figure 27. The number of clones decreases through the passages. The boxplots show 
the total number of clones identified for each passage of transplantation (Passages, X). 
Boxes define the 25th and the 75th percentiles; horizontal line within the boxes indicates the 
median and whiskers define the 10th and the 90th percentiles. 
 
 
In spite of the clonal selection within sequential passages, if we determined the correlation 
of frequency among all tumors through the passages, once again, we scored a very high 
correlation rate. R scores were never <0.6 and the mean R score was 0.88 (Figure 28), 
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suggesting the clones that survive serial transplantation have the same potential to populate 
the tumor. 
 
 
Figure 28. The correlation of frequency among all tumors through the passages is 
high. Heatmap of the R scores determined by Pearson correlation analysis. For each pair of 
samples we calculated the correlation of the distribution of the frequency of the clones 
identified. 
 
We next investihgated the molecular identity of the clones undergoing selection. First, we 
noticed that all clones of the X2 passages are also present in X1, and all clones of X3 are 
present in X2, with no new clones appearing in the subsequent passages. The only 
exception to this situation is mAPL18. Indeed, for this leukemia, in X2 we identified new 
clones not present in X1. However, these new clones are few, only 10 and 7 for Mouse ID2 
and ID3, respectively, and, more importantly, they contribute to a very low percentage of 
the tumor (≤ 0.35%, Figure 29), suggesting that they might have escaped detection in X1. 
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Figure 29. The new clones appearing in mAPL18 are present at very low frequency in 
the X2 tumor. The boxplots show the distributions of the percentage of tumor contributed 
by the new clones identified in the passage X2 of Mouse 2 (M2) and Mouse 3 (M3) of 
mAPL18. The contribution of these clones in X2 is always below 0.4%. Boxes define the 
25th and the 75th percentiles; horizontal line within the boxes indicates the median and 
whiskers define the 10th and the 90th percentiles. 
 
We then investigated if there is a correlation between frequency of each given clone within 
the tumor population and its  disappearance at the subsequent passage. To this end, we 
compared the distribution of the frequencies of clones specifically present only in X1 (X1-
specific), with that of clones common between X1 and X2. Same analysis was performed 
for the X2-X3 passages. For the X1-X2 passages, results showed no differences among the 
two groups of clones, indicating that low and high frequency clones have equal probability 
to survive the X1-to-X2 passage (Figure 30A). In contrast to what we observed for the X1 
passage, in the analyses of the X2-X3 passage, the clones specific only for X2 have a 
significant lower frequency in the tumor population compare to the one in common with 
X3 (Figure 30B). This indicates that in the passage from X2 to X3 passage only the most 
represented clones were able to survive transplantation.  
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Figure 30. The counter-selected clones are not necessarily the clones present at the 
lowest frequency within the tumor population. A) Distribution of the frequencies within 
the tumor population of the X1 clones present exclusively in the X1 passage of the 
leukemia (X1 specific) versus the distribution of clones in common with X2 passage (X1 
in X2). B) As for panel A for the clones present in the X2 passage of the leukemia: X2 
clones present exclusively in X2 samples (X2-specific) and in common with X3 (X2 in 
X3). 
 
Indeed, these data were confirmed also by the analysis of the percentage of tumor that the 
common clones contribute to in the previous passage of leukemia transplantation: while 
the clones in common with X2, in X1, covered a wide range of percentages of the tumor 
population, the clones in common with X3, in X2, contributed only to a very high 
percentage of the tumor (Figure 31A and 31B).  
 
 
Figure 31. The contribution to the tumor population of the common clones between 
passages is different between the X2 and the X3 clones. A) Tumor coverage (percentage 
of tumor), measured as percentage of each clone within the tumor population, for the 
clones in common between X1 and X2 both in the X1 and in X2 passage of 
transplantation. B) As for panel A for clones in common between X2 and X3.  
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Taken all together our data suggest that the clonal selection between passage X1 and X2 
appear to be deterministic, therefore not linked to the frequency of each clone within the 
tumoral population but to intrinsic biological properties of the transplanted cells. In 
contrast, the clonal selection between passage X2 and X3 appear to be more stochastic, 
very likely due to a bias in the sampling of the most represented clones that in X2 account 
for the majority of the leukemic population. 
 
4.3.8 The mode of evolution through the passages of each LIC is an intrinsic cellular 
property. 
We finally assessed how the clones evolve in time through the passages. We first 
determined which clones specifically appear or disappear completely from the X1 to the 
X2 passage. In agreement with the clonal selection reported in the previous paragraph, the 
clones that disappeared completely were in total 137 and represented ~52% of all (265) X1 
clones identified (Figure 32A). As described above, the clones that, instead, appeared in 
X2 are very few (only 17), are peculiar of mAPL18 and reach frequencies within the tumor 
population below 0.35% (Figure 32B and Figure 29).  
We then considered the clones in common between the passage X1 and X2: 110 in total. 
For these clones we determined the correlation of identity, measuring how the frequency 
of each individual clone within the tumor population varies between passages. According 
to their behaviour during clonal evolution, we identified three classes of clones: decreasing 
clones, growing clones and stable clones. The decreasing clones significantly decrease 
their frequencies in X2, they are 29 and account for 27% of the common clones (Figure 
32A). The vast majority of the clones are growing clones (64 clones, 58%), the one that 
increase their frequency from X1 to X2 (Figure 32B). The stable clones, instead, tend to 
maintain the same frequency between the two passages. These clones are the less 
represented (17 clones, 15%; Figure 32C). 
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Figure 32. Clonal evolution of AML between X1 and X2. A) Each line identifies a 
different leukemic clone. The graphs show the frequency distribution of each clones at 
each passage (X). Based on their frequency within the tumor population in the two 
passages the clones are divided in 3 classes: decreasing (A), growing (B) and stable (C). 
 
If we, then, looked at the further step of evolution in the X3 passage, the vast majority 
(36/39, 92%) of the decreasing clones, again, disappeared. Only 3 clones survived in X3 
but with lower frequencies compared to X2 (Figure 33A and D), again suggesting a strong 
clonal selection. Within the growing clones, only 8 constantly increased, expanding from 
X1 to X2 and expanding again in X3, and reaching frequencies that account for more than 
50% of the entire tumor population (Figure 33B and E). We did not score any stable clone 
within the leukemic population from X2 to X3, however, we noticed the presence of clones 
with a peculiar behavior. These clones account for half of the common clones (50 %). 
They increase their frequencies from X1 to X2 and tend to disappear in X3 (Figure 33C). 
Notably, this behavior was true even for those clones with a frequency up to 30% within 
the tumor population in the X2 passage (Figure 33F).  
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Figure 33. Clonal evolution of AML within the 3 passages of transplantation. A-C) As 
described in Figure 28. D-E) The boxplots show the frequency distributions within the 
tumor for each passage (X) of each class of clones: D, decreasing; E, growig; F, stable or 
variable. Boxes define the 25th and the 75th percentiles; horizontal line within the boxes 
indicates the median and whiskers define the 10th and the 90th percentiles.  
 
Taken all together, our data suggest that the different LICs within the leukemic population 
have different proliferation properties and can be mainly classified in 3 distinct classes 
based on their destiny through the passages: LICs that immediately exhaust, LICs that have 
a limited proliferative capacity and LICs that maintain their indefinite proliferative 
capacity. 
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 4.4 shRNA experiments 
 
4.4.1 Determination of the maximum complexity of the shRNA libraries supported by 
our leukemic models 
Pooled short hairpin RNA (shRNA) libraries have been successfully used to perform in 
vivo genetic-screens to identify novel oncogenes and tumor suppressors in murine models 
of liver cancer 25 and lymphoma 26, 27 .  
In order to define the leukemogenic potential of several genes in a single assay, we have 
performed an in vivo shRNA screening in xenotransplants of patient-derived leukaemia. 
Perform genetics screens in primary human tumours in vivo is quite innovative and it has 
not been reported yet. Instrumental for this study was the collection of human leukemic 
blasts able to grow in immuno-deficient mice and characterized by different and defined 
genetic alterations. Moreover, since the ability of AML to grow in a mouse model rely on 
LICs, this approach should, in principle, lead to the identification of crucial pathways for 
the growth of LICs in vivo.  
Particularly critical for the in vivo shRNA screening is: 
1. Determination of the multiplicity of infection, so that each cell is infected with a 
single viral particle and, therefore, has the integration of a single shRNA in its genome.  
2. Determination of the shRNA library complexity that the cancer model can 
support, or, in other words, how many genes can be efficiently targeted by a pool of 
shRNA in a given tumor sample.  
Regarding the first point, it has been previously published96 that a percentage of infection 
below 20% should ensure that each cell is infected with a single viral particle. To 
determine if this was true also in our experimental system, we conducted a virus titration 
assay by qPCR on the AML-IEO20 sample infected with the epigenetic library hEPI1 at 
MOI of 2 that, in our experimental setting, guaranteed that about 10% of blasts got 
infected. Half of the infected blasts were selected in puromycin (1 µg/mL) for 96 hours, 
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then, the DNA was extracted and used for the QPCR-based analysis as described in details 
in the section 3.9.2 of Materials and Methods96. Briefly, starting from the qPCR Ct values 
obtained for the infected sample and the standard curves both for viral and human 
sequences, we have calculated the number of integrant per cell. The results are reported in 
Table 15.  
 
Table 15. Calculation of number of integrations per cell. The results were obtained by 
qPCR analysis as reported in Material and Method section 3.9.2. Ct, Cycle threshold. 
WPRE, Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element 
(WPRE). hAlb, Albumin.  
	  
 
 
For the second point we had to consider that only LICs are able to engraft and proliferate 
significantly after transplantation into recipient mice83, therefore, in our experimental 
design, we should cover the complexity of the library within the stem cell population of the 
leukemia.  
In order to estimate the LIC frequency in our tumor samples, we have performed 
clonal tracking experiments and/or limiting dilution transplantation assays. In Table 14 is 
reported the LIC frequency estimated both by limiting dilution and clonal tracking 
experiments for one human and one mouse AML sample. As evident, these two methods 
gave similar results, therefore, for the other human samples we have performed only the 
limiting dilution approach that, for all samples analysed, gave a LIC frequency close to 1 
out of 1000 blasts (data not shown). Previous studies have shown that in order to ensure a 
good representation of all shRNA during the screening in vivo, we need to infect at least 5-
10 LICs per shRNA86,99. Considering that the infection of 50 million blasts is our limit of 
Sample Ct Average 
WPRE
Average 
hAlb
Integration/cell
AML-IEO20 
Not Infected
31.72 77 13,500 0.011
AML-IEO20 
Not Selected 24.68 10,900 20,000 1.09
AML-IEO20 
After Selection 24.4 13,000 20,500 1.271
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availability and/or manageability for both leukemic blasts and viral particles, and 
considering an average infection efficiency between 10 to 20%, we can screen about 1000 
different shRNAs. Finally, since in order to avoid off-target effects each gene has to be 
targeted by 10 shRNAs, our library can target about 100 genes.  
 
4.4.2 shRNA screenings in vivo in human AMLs 
One of the main problems we had in accomplishing this task concerned the infection 
procedure of human AML blasts with the lentiviral library. Most of the human AML blasts 
derived from our xenograft models did not survive in culture more than 16-24 hours 
(except for the sample AML-IEO20, that grew indefinitely in liquid culture) and, likely 
due to the fact that they were suffering, did not get infected. We thus tried many different 
infection and culture conditions and finally we managed to infect 4 different AML 
samples:  AML5 (t(1;2); NPM wt; FLT3 mutated); AML9 (complex karyotype; NPM WT; 
FLT3 WT); IEO20 (t(9;11); NPM WT; FLT3 WT); IEO23 (normal karyotype, mutant 
NPM, mutant FLT3). For AML-IEO20, the only sample able to growth in vitro, we also 
performed a puromycin selection for 96 hours before transplantation. The percentages of 
infection are listed in Table 16. 
Table 16. Percentage of infected cells with the shRNA library in different AML 
samples. The "incubation time" indicates how long the sample has been kept in culture 
before being transplanted in recipient animals. 
 
 
The samples were infected with a lentiviral library custom made by Cellecta Inc. 
containing 1204 shRNAs targeting 118 genes (10 shRNA for each gene plus positive and 
negative controls) that code for epigenetic modifiers involved in cancer development. 
AML Percentage 
of infection
Incubation 
time
Transplante
d Mice
AML5 1.20% 13h 2
AML9 21% 3h 2
AML-IEO23 20% 13h 2
AML-IEO20 10% 21h 3
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Before the transplantation, half of the samples was kept as reference and the other half 
transplanted in 2-3 recipient mice. As soon as the transplanted animals became sick we 
sacrificed them, collected the human blasts, extracted the DNA along with their reference, 
and used it to construct the library for high throughput sequencing. 
4.4.3 Library preparation 
Mice transplanted with infected AML blasts were monitored weekly by peripheral blood 
FACS analysis. As soon as the level of engraftment in the recipient mice reached 70% to 
90%, the animals were euthanized and the blasts from bone marrow and spleen were 
collected for DNA extraction and library construction. In Figure 34 is shown an example 
of library preparation obtained at the end of the amplification process for the DNA samples 
derived from animals transplanted with infected AML5. As shown in Table 16, although 
this is the sample with the lowest percentage of infection, nethertheless we were able to get 
the library for the sequencing step. In all the shRNA screening experiments, we could 
produce the library for sequencing also from the in vitro post infection reference DNA, 
probably thanks to the larger amount of starting DNA (25 million cells) compared to the 
clonal tracking experiments (half million cells). 
 
Figure 34. Library preparation from AML5 derived DNA samples. The PCR products 
were analyzed by 3,5% agarose gel. The band has the expected size of 259 bp. 100bp: 
100bp marker; M1 and M2: DNA samples extracted from the bone marrow of two mice 
transplanted with the AML5 infected blasts; Ctrl: negative control (no DNA); pRSI: 
positive control (purified plasmid). 
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4.4.4 Barcodes analysis  
The sequencing reads were aligned with "perfect match" to the library sequences provided 
by Cellecta in order to compare the frequency of each shRNA in the original population 
soon after the infection (referred as "in vitro"), and their frequency after expansion of the 
tumor in vivo. 
We first analyzed the reference samples. In these samples all the shRNAs are represented 
with a similar frequency (Figure 35) calculated as:  
 
𝑠ℎ𝑅𝑁𝐴	  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 	  𝑁𝑢𝑚𝑏𝑒𝑟	  𝑜𝑓	  𝑟𝑒𝑎𝑑𝑠	  𝑓𝑜𝑟	  𝑎	  𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐	  𝑠ℎ𝑅𝑁𝐴𝑇𝑜𝑡𝑎𝑙	  𝑛𝑢𝑚𝑏𝑒𝑟	  𝑜𝑓	  𝑟𝑒𝑎𝑑𝑠  
 
 
Figure 35. In vitro distribution of the 1204 shRNAs. On the x axis are reported the log2 
of the shRNAs frequencies, while on y axis the shRNA densities. Each line represents an 
"in vitro" AML sample. 
 
These data confirmed that the infection took place in a uniform manner and that all the 
shRNA are equally represented in the starting population, moreover, it was a good 
indication that the process of construction of the library was homogeneous and did not 
introduce main artefacts. We have also considered for each shRNA the second barcode, 
since, as described in detailed in section 3.7.2, the library is constructed in a way that each 
AML5
AML9
AML&IEO20
AML&IEO20P
AML23
sh
RN
A
de
ns
ity
Log2 shRNA frequency
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shRNA is associated with up to 12,415 different barcodes, allowing a "clonal" analysis of 
each shRNAs reads. In Table 17 are shown for each sample "in vitro" the number of reads 
and the number of "clones". According to these numbers, each shRNA is associated with 
an average of 370 barcodes. The frequency distribution of different barcodes for each 
shRNA is comparable (not shown).  
 
Table 17. Total number of reads and clones in the "in vitro" samples. 
 
 
We then analyzed the samples after the in vivo growth of the tumor.  We immediately 
noticed that all samples presented 2-3 highly expanded shRNAs that alone made up a large 
part of the whole sample. This expansion was more evident in some animals as: 
AML9_M1, AML9_M2, AML23_M1, AML-IEO20P_M2, AML-IEO20P_M3 (Figure 
36). 
 
Figure 36. shRNA frequencies distribution. On the x axis are represented all the samples 
derived from a single mouse after in vivo growth. On the y axis is reported the relative 
frequency of each shRNA in the sample.  
 
Sample # reads # clones
AML5 1.49E+07 3.70E+05
AML9 2.23E+07 2.55E+05
AML-IEO20 5.00E+07 4.13E+05
AML-IEO20p 2.66E+07 5.20E+05
AML23 4.08E+08 2.90E+05
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We argued that it was unlikely due to the biological effect of the shRNA, mainly for two 
reasons: i) the expanded shRNA was different in each mouse (even when transplanted with 
the same leukemia), and ii) it was not confirmed by the other 9 shRNA specific for the 
same gene. Our current hypothesis is that a single AML clone, derived from a single cell 
with a strong growth advantage, grew up in vivo generating a large part of the tumor. In 
support to this interpretation, when we examined all the barcodes associated with the 
expanded shRNA sequence we found that 99% of the reads were associated to a single 
barcode thus confirming the "clonal expansion" (Table 18). 
 
Table 18. Example of clonal expansion in the AML-IEO23 sample. 129 clones have 
been assigned to a SMARCB1 shRNA. The first clone represents the 99.88 % of the reads 
of the entire population for this shRNA. Highlighted in red is the clone eliminated after 
applying the 99.5%ile filter. 
	  
 
shRNA Barcode CT # reads n clones
SMARCB1.553 barfir_3814 740603 x1
SMARCB1.553 barfir_9452 150 x1
SMARCB1.553 barfir_3806 49 x1
SMARCB1.553 barfir_3807 45 x1
SMARCB1.553 barfir_3811 44 x1
SMARCB1.553 barfir_9821 43 x1
SMARCB1.553 barfir_9669 29 x1
SMARCB1.553 barfir_9509 26 x1
SMARCB1.553 barfir_3810 22 x1
SMARCB1.553 barfir_7961 21 x1
SMARCB1.553 barfir_7965 20 x1
SMARCB1.553 barfir_##### 15 x2
SMARCB1.553 barfir_##### 14 x2
SMARCB1.553 barfir_##### 13 x3
SMARCB1.553 barfir_##### 11 x4
SMARCB1.553 barfir_##### 10 x3
SMARCB1.553 barfir_##### 9 x2
SMARCB1.553 barfir_##### 8 x2 
SMARCB1.553 barfir_##### 7 x9
SMARCB1.553 barfir_##### 6 x4
SMARCB1.553 barfir_##### 5 x5
SMARCB1.553 barfir_##### 4 x4
SMARCB1.553 barfir_##### 3 x8
SMARCB1.553 barfir_##### 2 x20
SMARCB1.553 barfir_##### 1 x47
Total number of reads 741514
Reads analysed 911 (0,12%)
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The clonal expansion of few clones prevented the correct comparison of the frequency of 
different shRNAs before and after in vivo growth. In order to correct our data for the 
"clonality" issue, we have applied two alternative corrective methods: 
1. For each shRNA we have considered the reads up to the 99,5th percentile of the 
distribution of the second barcodes therefore eliminating from the analysis the outlier 
clones (see Table 18, as example).  
2. We have standardized the raw data applying the Z-score statistical method that uses the 
mean and standard deviation to transform raw scores in standard scores.  
Method 1: 
As shown in Table 19, this filter strongly reduced the number of reads considered for the 
analysis, therefore, after filtering, we have re-calculated the frequency of each shRNA 
within the population and compared their distribution to the ones obtained in the "in vitro" 
sample. 
 
Table 19. Number of reads and clones considered in shRNA screening. For each 
animal is reported the total number of reads obtained by NGS (# reads), the total number of 
clones (# clones) and the percentage of reads used for the analysis after applying  the 
99,5th percentile filter.  
	  
 
 
 
Sample # reads # clones % reads 
AML5 M1 1.67E+07 1.68E+04 32.99
AML5 M2 2.80E+07 3.07E+04 8.76
AML9 M1 1.75E+07 7.27E+03 1.8
AML9 M2 2.23E+07 6.55E+04 9.89
AML-IEO20 M1 4.56E+07 4.53E+04 20.81
AML-IEO20 M2 1.86E+07 1.54E+04 5.53
AML-IEO20 M3 3.25E+07 7.42E+04 30.22
AML-IEO20P M1 2.21E+07 5.04E+04 54.45
AML-IEO20P M2 2.29E+07 3.29E+03 10.97
AML-IEO20P M3 4.52E+07 9.67E+04 28.5
AML-IEO23 M1 2.45E+07 6.79E+03 4.06
AML-IEO23 M2 6.02E+07 1.53E+05 41.27
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As shown in Figure 37, the shRNAs frequencies distribution after in vivo growth is quite 
variable among mice and is characterized by a large number of depleted shRNAs.  
 
 
Figure 37. Distribution curves of the shRNAs frequencies in vivo (colored) and in vitro 
(black). Each color represents a single mouse. 
 
For comparative analysis, we have calculated the reads average for the 10 shRNA targeting 
the same gene, the relative frequency in the sample and then the enrichment or depletion 
compared to the reference with the following formula (FC Fold Change): 
logf 𝐹𝐶 = logf 𝑖𝑛	  𝑣𝑖𝑣𝑜	  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖𝑛	  𝑣𝑖𝑡𝑟𝑜	  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 
 
Method 2: 
We have calculated the frequency for each shRNA within the in vitro and the in vivo AML 
populations. Then, we have calculated the log2FC for each shRNA with the same formula 
reported above and, for each log2FC value, we have calculated the Z-score according to 
the following formula:  
𝑍 − 𝑠𝑐𝑜𝑟𝑒 = 	  𝑙𝑜𝑔2𝐹𝐶 − 𝑎𝑣𝑒𝑟𝑎𝑔𝑒	  𝑜𝑓	  𝑙𝑜𝑔2𝐹𝐶𝑠𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑	  𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	  𝑜𝑓	  𝑙𝑜𝑔2𝐹𝐶  
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In Figure 38 are shown the z-score distributions of the shRNAs log2FC for each animal. 
 
 
Figure 38. z-score distributions of the shRNAs log2FC for each animal. Each color 
represents a single mouse. 
 
For comparative analysis, we have calculated the average among the 10 Z-score-log2FC 
values targeting the same gene. 
At this point, we asked how the FC values for each mouse of a given AML sample 
correlate each other in the two methods. As shown in Table 20, the Pearson coefficients 
among animals are low, suggesting that the variability of the system is quite high, but are 
generally increased upon the introduction of the two normalizing methods. In particular, 
the 99.5%ile filter seems to work better with the AML9 and AML23 samples where the 
clonality issue was more dramatic, while the Z-score normalization is more effective in the 
others.  
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Table 20. Pearson correlations of the log2FC values among different animals. The 
mice were transplanted with the same leukaemia considering the raw, the 99,5th%ile and 
the z-score data set. 
 
 
 
We concentrated our attention on depleted shRNAs since they should target putative 
oncogenes that, in turn, can identify new therapeutic targets. In particular, we have ranked 
the FC values for each mouse and we have considered the shRNA targeted genes that fell 
in the first 15th%ile. The number of genes that are commonly targeted in more than one 
animal in the two methods are shown in Table 21. 
 
Table 21. Numbers of common targets among different animals. Dataset comparison 
between 99,5 and z-score analysis. 
  
 
 
Since in our experimental setting each AML has been divided in 2/3 animals and the 
"clonality" issue may have partially compromised our ability to cover library complexity 
within each single animal, we have decided, for each AML, to consider as depleted all the 
targeted genes resulting from the union of the lists coming from each animal. At this point, 
we have looked how many genes we have in common for each AML between the 99.5%ile 
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and the Z-score list. As shown in Figure 39, many genes are in common between the two 
methods. 
 
 
Figure 39. Common target for each AML between 99.5%ile and the Z-score lists. In 
orange is represented the 99.5%ile list, in green the Z-score list.  
 
Finally, for each AML we have considered only the genes targeted by depleted shRNAs in 
both the analysis. In Table 22, we show the genes both specific or in common to more than 
one AML. Strikingly, the two positive controls (PSMA1 and RPL30) are common to many 
samples, while the negative control (luciferase) is absent.  In bold, the genes we have 
selected to be validated in vivo. The validation strategy is described in the "discussion" 
section.      
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Table 22. Genes targeted by depleted shRNA in different AML. In red the positive 
control. In bold the gene we have selected for the validation step. 
 
 
 
 
 
 
 
 
 
 
 
Total in 
common
gene
AML20 AML20P AML23 AML5 AML9 1 PSMA1
AML20 AML20P AML5 AML9 1 BRD9
AML20 AML20P AML23 AML5 2 TRIM66, RPL30
AML20 AML5 AML9 2 UBE2A, TRIM24
AML23 AML5 AML9 1 CBX5
AML20 AML20P AML9 1 PRMT7
AML20 AML23 AML9 2 PRDM6, SETD7
AML20P AML23 AML9 1 SETD1B
AML5 AML9 1 BRD7
AML20 AML5 3 CHD9, SETDB2, KDM3A
AML23 AML5 2 UBE2I, CBX6
AML23 AML9 1 INO80
AML20 AML20P 4 SMC3, PRDM9, JMJD6, KDM4C
AML20 AML23 3 TET1, ING3, SETD4
AML20P AML23 1 DNMT3L
AML5 6 SMARCB1, CHD3, SMARCA2, PARPA1, KAT2A, KDM2A
AML9 8 PRMT1, DNMT3A, TET3, CHD1L, CHD4, KDM8. PRMT8, TET2
AML20 5 SETD1A, KDM4D, SMARCA4, SMC5, CBX2
AML20P 5 CBX4, MTA3, CHD2, PRDM13, KDM1B
AML23 6 PRDM16, KDM5D, SMC2, CTCF, PRDM8
AMLs
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5 DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   108 
The ability of cancer to evolve and adapt is a major challenge for therapy. Genetic 
plasticity, in fact, is one of the most important characteristic of cancer and consists in the 
sequential acquisition of somatic mutations that are selected by the tumor in order to 
acquire multiple cancer hallmarks26. Since the pool of somatic mutations is cell specific, 
within a cancer can coexist multiple genetically and functionally heterogeneous 
subpopulations. For these reasons, and given the increasing evidence of the heterogeneity 
of the cancer stem cells, determining the clonal composition inside the tumor population 
and the behavior of each cancer cell during tumor evolution is essential for understanding 
cancer biology and driving the study of new, more efficient, therapeutic approaches.  
The development of new technologies, that couple high-throughput sequencing to viral 
genetic barcoding, has allowed to obtain high resolution descriptions of in vivo cells 
dynamics with particular interest to clonality. In particular, using lentiviral-based 
approaches, a clonal tag (barcode) is stably incorporated into the genomic DNA so that 
each cell of a clone is identified by a unique barcode that can be resolved through 
sequence-based detection100. These technologies significantly increase the sensitivity of the 
analysis compared to PCR-based integration site identification, mainly biased by the 
choice of the restriction enzymes and by intrinsic bias of PCR amplification. The major 
benefits of this experimental approach are that it is unbiased, quantitative and provides 
accurate information on the relative proportion of different clones100.  
Up to date this approach has been largely used to study the clonal evolution of normal 
human and murine hematopoietic stem cells (HSCs) isolated from cordon blood or from 
bone marrow100-103. In particular, these studies addressed the issue of lineage 
differentiation during hematopoiesis, following the fate of barcoded HSCs. The authors 
have shown that, both in mouse and human, most cellular lineages derive from a small 
number of HSCs, however, not all HSCs have the same potential to give rise to more 
mature populations. Moreover, it has been observed that the contribution of different 
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clones dynamically changes with time. Indeed, there are directional changes 
(expansion/decline) and age-dependencies in the clonal output of individual HSCs. 
In our study we wanted to apply the same approach to track leukemia initiating cells 
(LICs) and follow their growth in vivo in order to understand how they contribute to tumor 
development and how they evolve. As experimental system we have used two leukemias: a 
murine leukemia derived from the PML-RARa knock-in model43 and a human leukemia 
engrafted in a immuonocompromised mouse model75  that bears the t(9;11) translocation 
and, therefore, expresses the MLL-AF9 fusion protein. This human sample is particularly 
aggressive compared to other human leukemia xenografts we have developed and allowed 
us to perform few rounds of transplantation in a relatively short time frame. As described 
in the "Results" section, for both leukemias, we have decided to analyze the data obtained 
from our clonal tracking experiments both from a “horizontal” and “vertical” perspective. 
The “horizontal” perspective allowed us to compare how the leukemic clones behave in 
different animals transplanted with the same leukemic sample within the same passage of 
transplantation. The “vertical” perspective allowed us to determine how the leukemic 
clones evolve in serial passages of transplantation. 
One of the main problems we faced in interpreting our data was related to the fact that 
most of the barcodes identified are represented by a very low number of sequencing reads 
and their contribution to the tumor mass is extremely low. These sequences could reflect 
the presence of barcoded cells that were transplanted into the recipient mice but were 
unable to proliferate or they could be due to background noise sequences, as previously 
shown104. In order to correct for technical bias and to determine the minimum number of 
cells detectable in our experimental system, we employed the use of a spike-in control, that 
had been previously applied in experiments of clonal tracking via barcoding in the 
mammary system105. The usage of "spike-in" single barcodes at known frequency before 
library preparation allowed us to understand that our system has a detection limit within 10 
to 100 cells. Moreover, it provided a formal proof that in our experimental settings, we 
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have a linear correlation between the number of sequence reads and the number of cells 
present in the samples. Interestingly, most of the low frequency barcodes are represented 
by a number of reads that are below our experimental detection limit, suggesting that they 
likely represents the background of our experimental system. We can not formally exclude 
that they represents randomly selected single cells that did not cycle (putative progenitors), 
however they account for cellular population that are represented by less than 10 cells and 
are never detectable in subsequent passages of transplantation, therefore, these clones do 
not contribute to tumor evolution.  
The clonal analysis at the first passage (X1) of transplantation provides the unique 
opportunity to evaluate the number of LICs present in the original leukemic population. Up 
to date, the gold standard method to determine the LIC frequency is the limiting dilution 
cell transplantation assay, in which leukemic cells are transplanted into recipient mice at 
decreasing doses; the proportion of animals that develop the disease is used to calculate, 
with a confidence interval, the LIC frequency in the original tumor sample. The main 
limits of this approach are: i) requires a large number of animals in order to reach 
statistical significance; ii) single LIC transplantation may be too stressful and alter the 
results. Based on the considerations listed above, for all our clonal analysis we decided to 
consider as real clones only the one with a number of reads above the threshold that 
corresponds to 10 cells. Strikingly, this cut-off allowed us to cover more than 99% of the 
tumor in all samples analysed. Moreover, the number of LICs we could estimate is very 
close to the number obtained by limiting dilution transplantation assays. These results 
suggest that, through our experimental strategy, we identified bona fide LICs and that the 
limiting dilution conditions do not seem to interfere with the ability of the LIC to engraft 
and grow in vivo. However, we do not know if with our approach of transplantation “in 
bulk” (500,000 leukemic cells/mouse) we are saturating the system. In other words, we 
cannot exclude that the number of LICs transplanted was higher than the one we report, 
but we could not score it simply because not all transplanted LICs had the chance to 
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engraft due to an intrinsic "space" constrain in vivo. In order to address this issue, we are 
currently performing new experiments in which we transplant increasing amount of 
infected blasts to understand if we are working under limiting conditions. Nonetheless, our 
experimental approach, compared to the one in limiting dilution, offers the great advantage 
to gain information regarding the LIC growing potential, because each LIC is univocally 
and permanently labelled and can be traced during its evolution. 
In the normal hematopoietic tissue, it has been reported that there is a clear asymmetric 
clonal distribution of HSCs in different skeletal compartments, indicating that different 
HSCs populate different BM niches even long-term101. Therefore, we first assessed which 
is the behavior of the LICs in term of their ability to populate different hematopoietic 
organs, asking if different leukemic clones are able to engraft and generate the disease in 
different hematopoietic organs. We compared the clonal composition of the leukemia in 
the main leukemic organs of the mouse: spleen and BM. In contrast to what observed for 
the normal HSCs, we did not score any difference in the clonal architecture of the 
leukemia in the two compartments. This strongly suggests that there is no clonal tropism 
for the distribution of the disease within the organism and all clones are distributed equally 
within the hematopoietic system. From a clinical point of view this would imply that a 
systemic treatment would have the same effect on all leukemic clones independently from 
their localization within the leukemic tissues.  
Analysing our clonal tracking experiments “orizontally”, therefore comparing the clonal 
evolution of the two leukemias in different mice but in the same passage of transplantation, 
we clearly showed that the clonal composition is very similar in terms of number of clones, 
in terms of frequency distributions and even of identity (in the passages were identity 
could be addressed). The common clones among all animals are indeed few, they are 
always the same, account for the vast majority of the tumoral population and, strickingly, 
within different animals they always grow to occupy the same proportion of the tumor 
population. These parameters are highly reproducible in all transplanted animals, with only 
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rare exceptions (two animals). This would indicate that each LIC has finite and limited 
“space” for proliferation. 
These properties of the LICs are reflected in a strong clonal selection observed in our 
“vertical” analysis, from passage to passage of the leukemia. While we can not exclude 
that from the X2 to the X3 passage of transplantation this selection could be due to a bias 
towards only the most represented clones in the sampling of the cells to be transplanted, 
we have shown that from X1 to X2 this is definitely not the case. Indeed, we observe the 
disappearance of clones that are present at very high frequency in the X1 passage. 
Moreover, notably, we scored also a class of LICs that expanded from X1 to X2 and then 
disappeared at the third round of transplantation. Our data indicates that, indeed, most of 
the LICs are endow with a limited proliferative potential that exhausts in just one or two 
rounds of transplantation and are not able to sustain leukemogenesis long-term. Indeed, a 
very minor proportion of clones (8%) is able to constantly expand throughout the passages. 
Finally, we never observed the appearance of new clones from one passage to the other, 
except for very few clones in case of the X2 of the murine leukemia mAPL18. However, 
all these new clones were present at very low frequency (<0.35%). It is worth to speculate 
that this could suggest the possible existence of LICs that remain dormant/quiescent in the 
first passage of transplantation and are able to re-enter the cell cycle only following a 
further transplantation stress. Further studies are necessary to establish if this could be a 
true hypothesis and to address this issue we are planning to perform clonal tracking 
experiments also in presence of treatment with 5-fluorouracil (5FU), that induces HSCs 
proliferation. 
A substantial characteristic of stem cells and cancer stem cells, as well, is believed to be 
their ability for self-renewal without loss of proliferation capacity with each cell division. 
Therefore, cancer stem cells are putatively immortal. In contrast to these believes, taken all 
together, our data strongly support a model in which each LIC possesses an intrinsic and 
highly variable replicative potential. Each LIC appear to be endowed with a determined 
   113 
capability of proliferation within the tumoral population and, in particular, each leukemia 
possesses a definite number of LICs able to propagate the disease long-term. These LICs 
tend to overgrow all other clones to constitute a very large proportion of the tumor. 
Moreover, based on the results of our clonal tracking experiments, we can speculate that 
the vast majority of the LICs are not immortal and tend to get old with time, loosing their 
fitness and their indefinite replicative potential.  
Development of cancer requires the accumulation of genetic and epigenetic changes that 
each confers a selective advantage to the cell at a specific stage of tumorigenesis. These 
changes include inactivation of onco-suppressors or activation of oncogenes. At the end, 
the tumor is the result of the complex alteration and intersection of different cellular 
pathways and, even though we can map these alterations by whole genome sequencing, is 
quite difficult to predict the epistatic relationship among them and which one is the most 
critical for tumor growth in a complex environmental system like the one in vivo. These 
reasons may explain why it has been so difficult to find good therapeutic targets that are 
usually selected in system in vitro and have to be validated first in animal model and, then, 
in humans. Moreover, we have to consider that in the last years it has been shown that in 
many tumors included AML, only a small subset of cells is able to reconstitute the entire 
tumor both using human tumors (xenograft models) or mouse tumors (transgenic models) 
leading to the Cancer Stem Cell (CSC) theory. The idea that CSCs are responsible for 
driving tumor growth and metastasis has important implications for the treatment of 
cancer. At present, most cancer therapies are targeted against the actively dividing, bulk 
population of tumor cells and not necessarily against the CSCs, which may account for 
resistance to treatments and recurrence of disease, even after prolonged periods of apparent 
remission. Increasing evidences suggest that in the future a good therapy should combine 
treatment direct against both the bulk and the CSC tumor populations. The screening we 
have performed is innovative under several points of view and overcome many of the 
problems just highlighted. It has been conducted entirely in vivo using AMLs xenograft 
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mouse models and, therefore, it identifies targets involved in the growth of the primary 
tumor in its natural environment and, since tumor growth in vivo relaies mainly on 
proliferation and expansion of CSCs, this system, for the first time, is highly selective for 
putative therapeutic target specific for the CSC population.  
Recent studies of the spectrum of somatic genetic alterations in acute myeloid leukemia 
have identified frequent somatic mutations in genes that encode proteins important in the 
epigenetic regulation of gene transcription. Genes such as 
ASXL1, DNMT3A, EZH2, IDH1/2, MLL1 and TET2 have been shown to be frequently 
mutated and/or involved in chromosomal rearrangements in patients with myeloid 
malignancies106. Mutations in these genes are known, or suspected, to affect the functional 
roles of these proteins, involved in modifying cytosine nucleotides on DNA and/or altering 
the state of histone modifications107-110. Since epigenetic changes induced by oncogenic 
stimuli are potentially reversible, the proteins involved in epigenetic regulation are 
potential druggable candidates. Therefore, we decided to use an shRNA lentiviral library 
able to interfere with the expression of genes that encode for epigenetic regulators. A 
further advantage of our screening has been the usage of a small number of mice and blasts 
allowing conducting the screening in more than one AML and leading to the identification 
both of tumor-specific and tumor-wide putative targets that might offer solutions of 
therapeutic intervention in a wide group of AML patients.  
Particularly important for this part of the project is to obtain an infected population that 
covers the complexity of library with only one integration per cells. This is critical because 
we want to be sure that the biological effect that we observe after screening, is the direct 
result of the action of one single shRNA. For these reasons, and also according with 
previous published data96, we decided to obtain a maximum efficacy infection of 20% and 
to transplant the cells right after the infection. With these condition we were able to obtain 
infected populations that cover all the library complexity, and more importantly, with one 
integration per cell.                                                                                                 
   115 
 
During the analysis, the main problem we have encountered is the clonality issue. In 
some animals the impact has been dramatic (AML5_M2; AML9_M1; AML9_M2, 
IEO20_M2; IEO23_M1; see figure 36 and table 18), in others the percentage of the tumour 
not covered by the expanded clones was larger allowing a more reliable analysis of the 
results. However, it is likely that this problem may have reduced our ability to cover the 
complexity of our library in vivo. Indeed, the correlation of the results obtained by 
different animals transplanted with the same AML is modest and tend to be lower for 
animals in which the clonal expansion was higher. For this reason, we considered as 
putative target genes the union and not the intersection among the lists coming from 
different animals transplanted with the same AML. Based on these considerations, we 
think that for the next experiments we need to modify our protocol as following: 
- Perform the clonal tracking experiments in order to evaluate how each AML sample 
grows, both in the xenograft models for human or in the syngeneic recipients for mouse. 
- Based on the clonal tracking information, calculate how many infections and animals 
have to be transplanted in order to have statistically significant data. 
For the time being, to face this problem we have applied two different normalizing 
methods: i) we have eliminated outliers clones from the in vivo samples and we have 
recalculated the shRNA frequencies in the resized samples; ii) we have considered the 
entire population and we have normalized the fold change values (FC) between the in vitro 
and the in vivo samples. Although the two methods are conceptually quite different, the 
genes targeted by the down-regulated shRNAs are fairly consistent with the two methods, 
and this prompted us to consider these common genes as putative targets and proceed with 
the validation protocol. 
It is interesting to note that the deregulation and/or overexpression of most of the identified 
potential targets listed in Table 21 are already reported to be involved in different types of 
cancer including leukemia. The criteria we have used for the selection of the genes to be 
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validated are the following: i) recurrence among different AML samples; ii) data available 
in the literature about their involvement in cancer progression; iii) recognised as possible 
therapeutic targets to develop specific inhibitors (http://www.thesgc.org/chemical-
probes/epigenetics).  
The TRIM family proteins are involved in tumorigenesis and tumor progression, affecting 
pathways such as cell proliferation, DNA repair and apoptosis as for example in 
promyelocytic leukemia111. CBX5 has been shown to be important in the regulation of 
pathways that control stemness in lung cancer112. Interestingly, we found different 
component of the SWI/SNF chromatin remodelling complexes previously associated with 
the development of solid tumors as the ovarian113, liver cancer114, renal carcinomas115 and 
pancreatic cancer116. Morever, very recently, it has been reported that SMARCA4 and 
SMARCD2 are required in the maintenance of AML in a murine model of MLL-AF9 
leukemia and, in particular, for leukemia self-renewal117. The bromodomain-containg 
protein 9 (BRD9) is also present in some SWI/SNF ATPase remodelling complexes118-120 
and it has been identified to have a copy number variation (CNV) in samples of non-small 
cell lung cancer (NSCLC)121 and in cervical cancer119. Moreover, it can be selectively 
target by a chemical probe122. PRDM protein family members are involved in gene 
expression regulation, modifying the chromatin structure directly, through the intrinsic 
methyltransferase activity, or indirectly through the recruitment of chromatin remodelling 
complexes. In our screening we have identified PRDM6, PRDM9, PRDM13 and PRDM16 
as potential leukemic target. In particular, PRDM9 is involved in meiotic recombination 
events and could induce pathological genomic rearrangement123  and PRDM16 is involved 
in human leukemic translocations and is highly expressed in some AML124.  
We found other enzymes characterized by methyltransferase activity as SETD1B and the 
PRMT1. Deregulation of SETD1B is associated with lung cancer125 and is recurrently 
amplified in melanoma, accelerating disease onset126 while overexpression of PRMT1 is 
associated to breast and prostate cancers127. 
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Another interesting class of enzyme we have scored in the screening are the histone lysine 
demethylases. Deregulation of these proteins has been associated in the development of 
cancer128 and inactivating mutations are present in multiple myeloma, carcinomas, 
glioblastoma, breast and colorectal cancer129,130. In particular, KDM4C is deregulated in 
the aggressive basal breast cancer subtype131. JMJD6, as for KDM4C, is involved in breast 
cancer, its deregulation drives cell proliferation and motility and it is a marker of poor 
prognosis132. Interestingly, JMJD6 was recently reported to interact and required for the 
activity of BRD4, a widely studied therapeutically target in AML133. 
For the validation step, our main limit is the impossibility to select a homogeneous AML 
population expressing the shRNA, since, except for AML-IEO20, our AML samples do 
not grow in vitro. To overcome this problem, we have cloned two shRNA for each gene 
we want to validate in a lentiviral vector in which the expression of the shRNA may be 
induced by administration of doxycycline, moreover, the same vector constitutively 
expresses the reporter gene eGFP. Briefly, we will infect and immediately transplant our 
AML samples with the shRNA expressing lentiviral particles. We will wait the expansion 
in vivo of the mixed (GFP+ and GFP-) AML population, then, we will sacrifice the animal, 
purify the GFP+ blasts by FACS sorting and we will retransplant them in recipient 
animals. At this point, we will induce the expression of the specific shRNA by doxycycline 
administration and we will monitor leukemia development compared to control animals.  
At the end of this validation step, we will be able to establish to which extent our screening 
results are reliable in identifying new putative therapeutic target for AML treatment. The 
big advantage is that these targets will be already validated in the pre-clinical model.  
If, as we believe, a fairly good number of targets will be validated in vivo, we can extend 
this approach to other samples in an effort to correlate classes of targets to molecularly 
defined AMLs.  
At the end of this project, we are confident we will have set up an innovative experimental 
protocol that can change the way we consider the importance of AML-specific molecular 
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alterations. So far they have been used mainly for studies on prognosis and risk 
stratification but their impact on therapeutic choices is poor. These studies will sign a great 
advance in the possibility, in the future, of having differentiated therapeutic approach 
specific for each molecular characterized AML subtype that will hopefully increase 
patients survival and decrease therapy related side effects. 
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